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Abstract
The thesis begins with a description of the history of tobacco usage, health effects 
related to tobacco consumption, the metabolism of nicotine and the analytical methods 
used for the determination of its metabolites.
The work described in this current study is related to the use of the Konig reaction for 
the colorimetric determination of nicotine and its metabolites. Two novel non-polar 
condensing reagents were prepared and evaluated as to their performance with an 
extensive range of individual nicotine metabolites. The work extends our basic 
knowledge of the analytical chemistry of this reaction particularly in relation to the 
molar absorptivity and partitioning of the coloured derivatives formed. It was found 
that each metabolite has its own unique molar absorptivity, a finding which has 
profound implications for the interpretation of this reaction when used quantitatively as 
a test for “Total Nicotine Metabolites” since it is increasingly recognised that nicotine 
metabolism may differ between individuals, ethnic groups and during different 
physiological states. In addition its possible utility as a colorimetric derivatisation 
procedure for the determination of nicotine concentrations by high performance liquid 
chromatography (HPLC) may also be compromised if cotinine alone is used for 
standardisation purposes.
The use of these novel derivatives was investigated in relation to their correlation with a 
specific radioimmunoassay (RIA) for cotinine and the ability of the test to discriminate 
between smokers and non-smokers. The use of more non-polar derivatives was found 
to result in a small enhancement of the discriminatory power of the reaction for the 
determination of smoking status. An excellent correlation was found between the RIA 
and the use of the Konig reaction. This work formed the basis of a paper published in 
the British Journal of Biomedical Science (K L Chambers, G A Ellard, AT Hewson and R F 
Smith (2001), "Urine test for the assessment of smoking status", British Journal o f Biomedical Sciences, 
58:61-65).
There has been considerable debate as to the precise nature of the derivatives formed 
during the Konig reaction. Part of this work has been dedicated to the elucidation of the 
definitive structures of these compounds. The evidence presented here suggests that the 
structure proposed by Rustemeier et al (1993) is the more likely of the proposed 
structures (Klaus Rustemeier, Demetrios Demetriou, Georg Schepers and Peter Voncken (1993), "High- 
performance liquid chromatographic determination of nicotine and its urinary metabolites via their 
l,3,diethyl-2-thiobarbituric acid derivatives", Journal o f Chromatography B, 613:95-103).
The work concludes with a consideration of the possible use of surfactants to enhance 
the procedure and enable the use of potassium thiocyanate rather than potassium 
cyanide during the reaction. Several combinations of anionic, cationic and neutral 
surfactants are investigated and their effects on the Konig reaction discussed.
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Chapter 1
Introduction
1.1 Historical aspects
Nicotine, in the form of tobacco products, has played a social and commercial part in 
human society for many centuries. The first recorded society believed to smoke tobacco 
were the Mayan tribes around 1000 BC. This is known through cave paintings, which 
the Mayan tribes left on the walls of ancient temples showing Mayan priests smoking 
through a pipe. During 470 to 630 AD, the Mayan tribes began to move throughout 
America, hence introducing tobacco to other parts of the continent, including the 
indigenous people of North America (http://www.bat.com and http://www.tobacco.org).
In 1492 Christopher Columbus was offered tobacco from the Arawak people of San 
Salvador, an island in the Bahamas, but it is believed Columbus did not fully understand 
the significance of the dried tobacco leaves presented to him and discarded them. Also 
in 1492, Rodrigo de Jerez and Luis Torres, two explorers returning from a trip into the 
interior of Cuba, stumbled upon villagers inhaling the smoke from burning dried 
tobacco leaves through a hollow Y-shaped piece of cane called tobago or tobaca. 
However, when Jerez returned to his home town, Ayamonte, he was accused by the 
holy inquisitors of “consorting with the devil” when they saw smoke coming from his 
mouth, and they imprisoned him for seven years, although by the time Jerez was 
released, smoking was common in Spain (http://www.bat.com and http://www.imperial- 
tobacco.com). However, it has also been reported that tobacco was not introduced to 
Spain until 1558, (some years later after Jerez was released from prison), when 
Francisco Fernandes, a physician, was sent by Phillip II of Spain to investigate the 
products of Mexico (http://www.tobacco.org). In 1570, Phillip II of Spain considered 
whether tobacco had any medicinal properties for possible commercial gain and
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commissioned the royal physician, Francisco Hernandez, with making a study in to the 
plant’s properties (http://www.bat.com).
In 1560 the French ambassador to Portugal, Jean Nicot de Villemain, was first reported 
to have sent tobacco and tobacco seeds to Paris from Portugal (Jackson 1941 and 
http://www.gallaher-group.com). Jean Nicot was believed to have recommended tobacco 
snuff to his royal patron, Catherine de Medici. The reason why Nicot recommended 
tobacco snuff is unclear, but it may have been used to treat her son Francis It’s migraine 
headaches (http://www.tobacco.org) or it may have been used to cure Catherine’s own 
severe migraines by making her sneeze (http://www.bat.com). In Nicot’s honour the 
tobacco genus Nicotiana was later given its botanical name (Jackson 1941 and 
http://www.bat.com). However, there are reports that tobacco was introduced to France in 
1556 by a revolutionary monk, Thevet. Thevet claims that he was first to transport 
Nicotiana tabacum from Brazil, but this has been disputed by many 
(http://www.tobacco.org).
Tobacco is thought to have been first introduced to England in 1564 by Sir John 
Hawkins and his ship’s crew (http://www.tobacco.org and http://www.gallaher-group.com) . In 
1573, Sir Francis Drake returned from America with what was thought to be the first 
consignment of Nicotiana tabacum, and the potato, to the UK and in 1585, he 
introduced smoking to Sir Walter Raleigh. In 1586, Sir Walter Raleigh sailed to 
America where he met Ralph Lane, the first governor of Virginia who is believed to 
have taught Raleigh to smoke a clay pipe. Raleigh on his return also brought large 
amounts of tobacco from the “New World”.
An Englishman, John Rolfe cultivated the first successful commercial crop of “tall 
tobacco” in 1612 (http://www.cnn.com and http://www.tobacco.org) and by 1619 the first 
Africans were brought as slaves to help with the tobacco crop on Rolfe’s plantation; 
over the next two centuries, the growth of the tobacco trade largely fuelled the demand 
in North America for slave labour (http://www.cnn.com).
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By 1800, tobacco was also being commonly used as an insecticide in England (Leistikow 
et al 1999). Today nicotine solution is still used as an effective insecticide to kill soft- 
bodied insects such as plant lice. The nicotine solution is usually sold as 40 percent 
nicotine sulphate solution to prevent volatilisation, and is widely used throughout the 
world as a relatively cheap and environmentally friendly insecticide. The threshold 
limit for commercial exposure to mcotine is at a concentration of 0.5mg/m (Gorrod and 
Jacob 1999).
In 1881, James Bonsack, a Virginian inventor, invented a cigarette machine that could 
produce 120,000 cigarettes a day and he was also granted the first cigarette machine 
patent. Also in 1881, James Buchanan “Buck” Duke entered the cigarette business in 
Durham, North Carolina, USA. By 1884 Buck Duke had decided to expand his tobacco 
business nationally and headed to New York. He also purchased two Bonsack cigarette 
machines, and was able to produce 120,000 cigarettes in 10 hours from a single machine 
by the end of the year (http://www.tobacco.org) and 21 years later he became the first 
chairman of British-American Tobacco, (BAT) (http://www.bat.com).
During World War II (1939-1945) servicemen and women were supplied with cigarettes 
as part of their rations and by the end of the war cigarette sales were at an all time high. 
This could be directly linked to the returning servicemen and women who became 
addicted to smoking during the war.
In 1965 cigarette advertisements on television were banned but it was not until 1991 
that pipe tobacco and cigar advertising were withdrawn under a European Union 
Directive on broadcasting (Ash basic facts No 4,2002).
The World Health Organisation, as part of their 40th anniversary set up the first World 
No Tobacco Day in 1988. The aim of the day was to promote global attention to the 
tobacco smoking epidemic and the preventable death and disease it causes
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(http://www.5.who.int) . They used the slogan “Tobacco or health: The choice is yours” to 
promote their campaign.
On 7th February 1999, the Royal family announced the removal of the Royal seal of 
approval from the tobacco company Gallaher Limited, makers of Benson and Hedges 
and Silk Cut cigarettes, ending a 122 year agreement (http://www.news.bbc.co.uk).
1.1.1 Historical health effects
The health effects associated with tobacco, whether beneficial or not have been reported 
for over four hundred years. At first tobacco was recommended by European doctors 
around 1577, as a cure for toothache, falling fingernails, worms, halitosis, lockjaw and 
cancer (http://www.tobacco.org). Smoking tobacco was even thought to have a protective 
effect from the great plague (1665-1666) and for this reason, smoking was made 
compulsory at Eton. It is said that every schoolboy was requested to smoke in school, 
every morning, under the supervision of a master, and the boys were whipped if they 
failed to do so (http://www.imperial-tobacco.com).
However, by 1761, the tables had started to turn and the negative health effects 
associated with tobacco were starting to emerge. In 1761, Dr Percival Pott, a physician 
in England theorised, that there may be a connection between cancer and exposure to 
soot due to the number of chimneysweepers developing cancer of the scrotum. In the 
same year, another physician from London, John Hill published “cautions against the 
immoderate use of snuff”. In this publication he warned snuff users that they were 
vulnerable to developing cancers of the nose and later, in 1791, he reported cases in 
which snuff had caused nasal cancers (http://www.tobacco.org) and Sammuel Thomas von 
Soemmering of Maine in 1795, reported that he had observed cancer of the lip in pipe 
smokers (http://www.tobacco.org). It was not, however, until as late as 1912 that Dr Isaac 
Adler first suggested a strong link between smoking and lung cancer 
(http://www.tobacco.org).
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In 1908, legislation in England was brought in to prohibit the sales of tobacco to under 
16s, based on the belief that smoking stunted childrens growth (http://www.tobacco.org). 
This law was then reinforced by the 1991 Childrens and Young Persons (Protection 
from tobacco) Act (Ash Basic Facts No 4,2002).
In 1928, a study carried out by Lombard and Doering examined 217 cancer victims. 
They compared the age, gender, economic status, diet, smoking and drinking habits of 
these patients. Overall, their findings suggested that cancer rates were only slightly less 
for non-smokers but that 34 of 35 site-specific (lung, lips, cheek and jaw) cancer 
sufferers were heavy smokers (http://www.tobacco.org).
The first formal statistical evidence that lung cancer was related to tobacco was 
published in 1929 by Fritz Lickint of Dresden. Lickint also argued that since men 
smoke tobacco more than women, then this can explain why lung cancer is four or five 
time more likely to develop in men than women (http://www.tobacco.org). In 1930, another 
statistical correlation was made between cancer and smoking by researchers in Cologne, 
Germany (http://www.tobacco.org).
A British researcher, L M Johnston reported in 1942, that he had successfully 
substituted nicotine injections for smoking and concluded that the essence of tobacco 
smoking is the tobacco and not the smoking. He also concluded that the satisfaction of 
smoking could be obtained from chewing tobacco, from snuff taking and from 
administration of nicotine (http://www.tobacco.org).
During 1950, three important epidemiological studies linking smoking and lung cancer 
were published. Morton Levin published the first major study linking smoking to lung 
cancer. Ernst Wynder and Evarts Graham published, “Tobacco smoking as a possible 
etiologic factor in bronchiogenic carcinoma: A study of 684 proved cases” and found 
that 96.5 percent of lung cancer patients interviewed were moderate to heavy chain 
smokers and two British researchers, Richard Doll and Bradford Hill, published
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findings that suggested heavy smokers were fifty times more likely to contract lung 
cancer than non-smokers (http://www.tobacco.org).
Richard Doll and Bradford Hill in 1952 reported the results of a four-year study 
comparing 1,465 lung cancer patients to an equal number of patients with other diseases 
of the same age and sex. They concluded that lung cancer patients are more likely to be 
smokers and even more likely to be heavy smokers (http://www.bat.com).
In 1956, Ernst Wynder reported that he applied 40 mg of tobacco tar to mice, three 
times a week and within 10 months, the first signs of cancer had started to appear. By 
the end of the second year, 59 percent of the mice had developed papillomas, and 44 
percent had developed carcinomas, although none of the control animals that were 
painted with acetone (used as the solvent for the tobacco tar) developed any lesions 
within this time (Wynder 1956).
In 1957, Winea Simpson found that the incidence of premature births and of all the 
complications that go with prematurity was twice as great for smoking mothers as it was 
for non-smoking mothers. This report also confirmed that children of smokers are 
likely to weigh less and they are more likely to be either still bom or die within one 
month of birth (http://www.tobacco.org).
During the 1960s, health warnings started to appear on the dangers of smoking and over 
the next forty years a variety of studies were carried out to determine the health effects 
associated with smoking and advancements in smoking cessation including nicotine 
replacement therapy. Such advances will be discussed in more detail in 1.4 and 1.5.
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1.1.2 History of the chemistry associated with nicotine
Tobacco is known to have been available from around 1570, although it was not until 
the early 19th century that the chemical identification of nicotine was described. Cerioli 
in 1807 described the isolation of the “olio essenziale” of tobacco (Holmstedt 1988 and 
Gorrod and Jacob 1999) and in 1809 Vauquelin independently reported the same potent, 
volatile and colourless substance which he called “essence de tabac” (Jackson 1941, 
Holmstedt 1988 and Gorrod and Jacob 1999). Vauquelin’s discovery was also confirmed by 
Hermbstadt in 1822.
Wilhelm Heinrich Posselt and Ludwig Reimann, two students at the University of 
Heidelberg, isolated nicotine from tobacco in 1828 and in 1843 Melsens first described 
the chemical empirical formula of nicotine as C10H 14N2 (Holmstedt 1988). Barral, in 1847, 
confirmed Melsens findings and determined the molecular weight of nicotine to be 162 
(Holmstedt 1988). Nicotine was first synthesised in 1895 by Pictet and Crepieux (Holmstedt 
1988) and in 1904 Pictet and Rotschy described the chemical isomerism of nicotine, 
although it was Auzies who obtained the French patent 425,370 (January 3 1911) for the 
synthesis of nicotine (Jackson 1941).
In 1978 Pitner et al suggested it would be desirable to obtain a more detailed 
conformational picture of nicotine to aid in the interpretation of its physiological 
activity in terms of structure-function relationship and proposed a spatial orientation of 
natural nicotine ((S)-nicotine) (Pitner etal 1978).
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1.2 Chemical properties of nicotine and tobacco
The compound known to establish tobacco dependence is nicotine. The chemical 
properties of nicotine have been well documented (Merck 1996 and Jackson 1941). Nicotine 
is a natural liquid alkaloid produced from the dried leaves of the Nicotiana tabacum or 
Nicotiana rustica plant and usually consists of 2-8 percent of the dry weight of the cured 
leaf.
For many years nicotine was considered to be the only alkaloid in tobacco, although it is 
now known that other alkaloids, for example anabasine, anatabine, isonicoteine, 1 -N- 
methylanabasine, 1-iV-methylanatabine, nicotelline, nicotimine, nicoteine, nicotyrine and 
nomicotine can be isolated from tobacco and other plants (Jackson 1941).
Nicotine is a colourless to pale yellow oily liquid with a characteristic odour. However, 
on exposure to air and light or even on standing in the dark in a sealed bottle, the 
colourless or pale yellow liquid adopts the characteristic brown colour of stored 
nicotine.
Nicotine is a tertiary amine consisting of a pyridine and pyrrolidine and is chemically 
known as 3-(l-methyl-2-pyrrolidinyl)-pyridine, l-methyl-2-(3-pyridyl) pyrrolidine or P- 
pyridyl-a-N-methylpyrrolidine. Nicotine has an empirical formula of C10H 14N2 and a 
molecular weight of 162.23 (figure 1.1). When (S)-nicotine is boiled at 250°C with 
potassium tertiary butoxide, it racemizes. The active isomer is (S)-nicotine, which 
binds to nicotinic cholinergic receptors, and is the isomer present in tobacco, whereas 
(R)-nicotine is only a weak agonist of cholinergic receptors. During smoking, some 
racemization takes place, exposing the smoker to small quantities of (R)-nicotine (Zevin 
et al 1998).
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Figure 1.1: Molecular structure of (S)-nicotine
Tobacco smoke is made up of “sidestream smoke” from burning tip of the cigarette, and 
“mainstream smoke” which is inhaled by the smoker. Tobacco smoke contains 
thousands of different chemicals, which are released into the air as particles and gases 
and these chemicals are often found at a higher concentration in sidestream smoke, than 
mainstream smoke (Ash fact sheet no 1 2 , 2 0 0 1 ). Sidestream smoke accounts for nearly 85 
percent of the smoke in a room, and approximately one-half of the smoke generated 
from a lighted cigarette is emitted from the smouldering cigarette between puffs (Ash 
fact sheet no 1 2 , 2 0 0 1  and Zhong et al 2 0 0 0 ) Together both sidestream and mainstream smoke 
form the major components of environmental tobacco smoke (ETS).
Cigarette smoke is composed of two phases, the volatile and the particulate. The 
volatile gaseous portion comprises of about 95 percent of cigarette smoke by weight and 
consists of approximately five hundred gaseous compounds; these include nitrogen 
oxides, carbon monoxide, carbon dioxide, ammonia, hydrogen cyanide and benzene. 
The remaining 5 percent of the cigarette smoke makes up the particulate phase and is 
composed of approximately 3500 different compounds, which include the major 
alkaloid nicotine (Zevin and Benowitz 1999) (table 1.1). The particulate matter minus its 
alkaloids and water content is called tar. Cigarette tar is known to contain many 
carcinogens, such as polynuclear aromatic hydrocarbons, iV-nitrosamines and aromatic 
amines (Zevin and Benowitz 1999).
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VAPOUR PHASE AMOUNT PARTICULATE PHASE AMOUNT
Carbon monoxide 10-23 mg Particulate matter 15-40 mg
Carbon dioxide 20-40 mg Nicotine 1-3 mg
Carbon sulphide 18-42 pg Phenol 60-140 pg
Benzene 12-48 pg Catechol 100-360 pg
Toluene 1 0 0 - 2 0 0  pg Hydroquinone 110-300 pg
Formaldehyde 70-100 pg Aniline 360 ng
Acrolein 60-100 pg B enz[a] anthracene 20-70 ng
Acetone 100-250 pg Benzo[a]pyrene 20-40 ng
Pyridine 16-40 pg Quinolone 0.5-2 pg
Hydrogen cyanide 400-500 pg 2-Toluidine 160 ng
Nitrogen oxides 100-600 pg Cadmium 1 0 0  ng
Acetic acid 330-810 pg Polonium-210 0.03-0.5 pCi
Methyl chloride 150-600 pg Benzoic acid 14-28 pg
Table 1.1 Major components of fresh, undiluted mainstream smoke of non-filtered 
cigarettes
The amount of nicotine contained in cigarettes is not specified by the tobacco 
manufacturers and because nicotine is obtained from tobacco plants, the nicotine 
content will vary among and within different species of tobacco plants. Benowitz et al 
(1983) measured the amount of nicotine present in 15 American cigarette brands. Their 
findings suggested that the average cigarette contained 1.5 percent nicotine by weight, 
and that low tar/nicotine (low tar) cigarettes tended to have a higher concentration of 
nicotine compared to “regular” cigarettes. However, low tar cigarettes contained less 
tobacco per cigarette and so low tar cigarettes are not low tar because they contain less 
nicotine per cigarette, but because of filtration and ventilation characteristics which 
remove tar and nicotine and/or dilute smoke with air (Benowitz 1988a).
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1.3 The metabolism of nicotine
Nicotine is a weak base with a pKa of 8.0 (Benowitz 1988b), and consequently its 
absorption, excretion, pharmacology and toxicology is pH dependent. The pH of 
tobacco used for most American cigarettes, is acidic (pH 5.5). Nicotine at this pH is 
mostly ionised (positively charged) and therefore very little nicotine is absorbed through 
the buccal mucosa, even when it is held in the mouth. However, the pH of tobacco 
smoke from air-cured tobaccos, such as that used for cigars and pipe tobacco is alkaline 
(pH8.5), and therefore nicotine at this pH is mostly unionised and consequently is 
readily absorbed from the mouth (Benowitz 1988a and Zevin et al 1998). Chewing tobacco, 
snuff and nicotine gum are also buffered to an alkaline pH to facilitate nicotine 
absorption (Benowitz 1988a).
Nicotine is known to be readily absorbed through the skin, mucous membranes and 
lungs and is known to have a variety of pharmacological actions on various systems 
within the body. Once nicotine from cigarette smoke reaches the small airways and the 
alveoli of the lung, it is buffered to physiological pH (Zevin et al 1998), where 
approximately 31 percent of nicotine is in the unionised form and can therefore cross 
the cell membranes (Benowitz 1988b). As nicotine is rapidly absorbed, it enters the blood 
circulation and is distributed to various tissues, including the brain. Nicotine is thought 
to the reach the brain approximately 10 to 20 seconds after smoking and at the same 
time arterial levels of nicotine are thought to exceed venous levels by two to six-fold. 
The brain and plasma levels then decline very rapidly due to the distribution o f nicotine 
to the peripheral tissues or elimination from the body (Zevin et al 1998).
Tobacco may be smoked, chewed or ingested intranasally as snuff and approximately 
80-90 percent of ingested nicotine is altered in the body. Metabolism primarily occurs 
in the liver but also can occur in the kidney and a significant degree of inhaled nicotine 
may be metabolised by the lung (Benowitz et al 1994). It is known that approximately 70- 
80 percent of all nicotine is converted to cotinine. The remaining nicotine is converted 
to various nicotine metabolites via first phase or second phase metabolism (figure 1 .2 )
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Figure 1.2 Proposed pathway for the metabolism of nicotine
1.3.1 Phase I metabolism of nicotine
Nicotine is primarily metabolised to cotinine or nicotine 1 '-TV-oxide, by C- and N- 
oxidation respectively. The metabolic transformation of nicotine to cotinine in 
mammals consists of a two step reaction. The first step involves the microsomal 
cytochrome P450 system which catalyses nicotine to nicotine-A- 1 (5 ^iminium ion 
(McCracken et al 1992, Nakajima et al 1996 and Messina et al 1997).
Nicotine-A- 1 (5 Mminium ion was first reported to act as an intermediate in the metabolic 
pathway between nicotine and cotinine (Murphy 1973). Murphy (1973) reported that the 
formation of nicotine-A- 1 (5 ^iminium ion is catalysed by an enzyme system that has the 
properties of a mixed function oxidase and that the initial product of the oxidase 
reaction is likely to be 5 '-hydroxynicotine, although it may be possible that the 
formation of the nicotine-A- 1 (5 ^iminium ion could occur via direct dehydrogenation, 
but this pathway is less likely.
Gorrod and Hibberd (1982) confirmed that nicotine-A- 1 (5 ^iminium ion acted as an 
intermediate in the metabolic pathway between nicotine and cotinine. The conversion 
of the iminium ion to cotinine is then mediated by cytosolic aldehyde oxidases to form 
cotinine (McCracken et al 1992 and Nakajima et al 1996). Various enzymes involved in the 
conversion of nicotine to cotinine, have also been suggested and include, CYP2A6, 
CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP2F1 and CYP2C8 (Flammang et al 
1992, and McCracken et al 1992). McCracken et al (1992) concluded that it is possible that 
CYP2B6, CYP2D6 and CYP2A6 can mediate the conversion of nicotine to cotinine, 
although CYP2B6 is not constitutively expressed in human liver and therefore will be 
relatively unimportant in the metabolism of nicotine in most individuals. However, 
Messina et al (1997) concluded from their study that CYP2D6 is also not important in 
nicotine metabolism in humans and suggested that CYP2A6 was the principal 
cytochrome P450 involved in nicotine metabolism.
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Nicotine may be further metabolised by microsomal flavin monooxygenases to form 
nicotine 1 W-oxide or by iV-demethylation via nicotine- A1 (6) iminium ion to form 
nomicotine (Nguyen et al 1976 and Pacific et al 1992). Nicotine- l'JV-oxide can also be 
reduced back to nicotine in man by the bacteria in the gastrointestinal tract (Gorrod and 
Jacob 1999).
Cotinine can be excreted unchanged or be further oxidised at either the carbon or 
nitrogen centres to form other metabolites. Providing that the cytochrome P450 
enzyme, CYP2A6 is present and active (Nakajima et al 1996), hydroxylation at the 3 '- 
position can occur to form either cis- or tram -3 '-hydroxycotinine, although in humans 
the trans isomer is predominant (>98 percent) (Jacob et al 1990). Hydroxylation can also 
occur at the 5'-position to form 5'-hydroxycotinine (Dagne et al 1974), and under 
physiological conditions 5'-hydroxycotinine predominates over its open tautomer 4-(3- 
pyridyl)-4-oxo-jV-methylbutyramide. Both cotinine and 5'-hydroxycotinine can be 
further converted to the corresponding TV-oxides by oxidation of the pyridyl nitrogen 
(Dagne et al 1972 and Schepers et al 1999).
Neurath et al (1987) reported that although trans-3 '-hydroxycotinine had been known 
since 1963, it had not been measured quantitatively and they found that trans-3'- 
hydroxycotinine was excreted the most in urine compared to cotinine, nicotine, 
nicotine-lW-oxide and nomicotine. Results obtained by Benowitz et al (1994) also 
confirmed that trans-3 '-hydroxycotinine is the major urinary metabolite of nicotine, 
accounting for an average of 38 percent of all metabolites, whereas cotinine and 
nicotine account for 15 and 10 percent of urine metabolites, respectively. They also 
suggested that the pattern of metabolism is generally similar when nicotine is absorbed 
following inhalation of tobacco or is absorbed transdermally.
Norcotinine can be formed either by TV-demethylation of cotinine (Dagne and Castagnoli 
1972 and Schepers et al 1999), or by oxidation of nomicotine (Wada et al 1961 and Aislaitner et al 
1992).
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Both cotinine and norcotinine can be converted into metabolites that possess a pyridyl 
moiety attached to a modified butyric acid residue. 5 '-Hydroxycotinine is further 
metabolised to 4-(3-pyridyl)-4-oxo-7V-methylbutyramide, which is further converted to 
4-(3-pyridyl)-4-oxobutyric acid by a single enzymatic hydrolytic reaction rather than by 
iV-demethylation followed by hydrolysis of the amide (Gorrod and Jacob 1999). 4-(3-
Pyridyl)-4-oxo-butyramide is derived from norcotinine and can be hydrolysed to 4-(3- 
pyridyl)-4-oxobutyric acid (Eldirdiri et al 1997), which can be derived from either cotinine 
or norcotinine.
Sai and Gorrod (1995) carried out in vitro studies to determine if 4-(3-pyridyl)-4- 
oxobutyric acid is further metabolised and their results showed that it is converted by 
reduction to the corresponding carbinol 4-(3-pyridyl)-4-hydroxybutyric acid which 
cyclises to 5-(3-pyridyl)-tetrahydrofiiran-2-one. Bowman (1968) showed that when 5- 
(3-pyridyl)-tetrahydrofuran-2-one was administrated to rats, five Konig positive 
metabolites were detected in their urine samples; these included 4-(3-pyridyl)-4- 
hydroxybutric acid and 3-pyridylacetic acid. 3-Pyridylacetic acid has been detected in 
the urine samples taken from animals or man after cotinine (Bowman et al 1964 and 
McKennis etal 1964), nicotine (Kyerematen etal 1988 and Schepers etal 1993) or 4-(3-pyridyl)-4- 
oxobutyric acid (McKennis et al 1964) was administered and it is now accepted that 3- 
pyridylacetic acid is an end metabolite of nicotine phase I metabolism in mammalian 
systems.
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1.3.2 The role of the cytochrome P450, CYP2A6
Cytochrome P450 is a superfamily consisting of haem thiolate enzymes, which are 
involved in the metabolism of numerous endogenous and exogenous compounds that 
include steroid hormones, fatty acids and a variety of clinical drugs (Oscarson et al 1998). 
This superfamily consists of 74 families (CYP1 to CYP118), however only CYP1, 
CYP2 and CYP3 are mainly involved in the metabolism of foreign compounds in 
humans (Yokoi andKamataki 1998) and it is thought that the CYP2 family and in particular, 
CYP2A6 is the principal cytochrome P450 involved in nicotine metabolism (Messina et al 
1997). CYP2A6 is also responsible for coumarin-7-hydroxylase activity in humans and 
is involved in the metabolic activity of several procarcinogens including aflatoxin B 1 
and 4-(methylnitrosamine)-l-(3-pyridyl)-l-butanone (NNK) (Kitagawaetal 1999).
Genetic polymorphisms of CYP2A6 have been identified as CYP2A6*1A, 
CYP2A6*1B, CYP2A6*2, CYP2A6*3, CYP2A6*4 and CYP2A6*5. Initially three 
CYP2A6 alleles were discovered, a wild type CYP2A6*1, CYP2A6*2 and CYP2A6*3 
(Yamano et al 1990, Femandez-Salguero et al 1995). Yamano et al (1990) reported that the 
CYP2A6*2 allele consisted of a single amino acid substitution (Leul60His) and 
encodes for an unstable and inactive enzyme. Femandez-Salguero et al (1995) 
suggested that the CYP2A6*3 allele may encode for an inactive protein because it 
appears to be generated by multiple gene conversions between CYP2A6 and CYP2A7 
(an allele that also encodes for an inactive protein) in exons 3, 6  and 8 .
Individuals with the CYP2A6*2/3 and CYP2A6*3/3 genotype have no CYP2A6 
mediated metabolism. Tyndale et al (2001) reported that livers taken from 
heterozygous Caucasians (CYP2A6*l/2 and CYP2A6*l/3) have 50 percent of the 
CYP2A6 mediated metabolism when using nicotine as a substrate in vitro. This 
suggests that if two active forms of the gene are inherited, normal nicotine metabolism 
will occur and an inheritance of one or more defective genes will then reduce their 
ability to metabolise nicotine. Tyndale et al (2001) looked at a group of individuals 
who were tobacco dependent smokers who had one defective allele (CYP2A6*2 or
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CYP2A6*3) and one active allele (CYP2A6*1) and found that they smoked 
significantly fewer cigarettes per day and per week than tobacco dependent smokers 
without a defective allele (i.e. homozygous for the wild type allele CYP2A6*1)
A further three alleles were then discovered, CYP2A6*4, which deletes the whole 
CYP2A6 gene (Nunoya et al 1999 and Oscarson et al 1999a), CYP2A6*1B and CYP2A6*5 
(Oscarson et al 1999b). The CYP2A6*1B allele consists of a gene conversion with 
CYP2A7 in the 3 '-untranslated region but the effect of this allele on CYP2 A6  activity is 
unclear, whereas the CYP2A6*5 allele encodes for an unstable enzyme due to a point 
mutation in exon 9 leading to a single amino acid substitution (G479V), as well as the 
gene conversion in the 3 '-untranslated region (Oscarson et al 1999b).
Pianezza et al (1998) suggested that a group of individuals, lacking the genetically 
variable enzyme CYP2A6, have an impaired nicotine metabolism and therefore are 
significantly protected against becoming tobacco dependent smokers. Pianezza et al 
(1998) also suggested that individuals carrying CYP2A6-null alleles might have a 
decreased risk of developing tobacco-related cancers and other medical complications. 
This could be due to one of two factors. The main factor is that these individuals have a 
decreased risk of becoming a smoker, although, if they do become a dependent smoker, 
they are more likely to smoke less than those without impaired nicotine metabolism. 
The second factor is that tobacco smoke contains nitrosamines, which can be activated 
to carcinogens by CYP2A6, so individuals who carry CYP2A6-null alleles may also be 
less efficient at activating tobacco-smoke procarcinogens to carcinogens.
Ethnic differences in the metabolism of nicotine have been reported (Messina et al 1997, 
Perez-Stable et al 1998 and Benowitz et al 1999). Perez-Stable et al (1998) reported that serum 
cotinine concentration per cigarette smoked is significantly higher and the intake of 
nicotine per cigarette tends to be higher in black smokers, compared to white smokers. 
They also suggested that blacks metabolise cotinine significantly more slowly, 
compared to whites. Therefore, as the intake of nicotine is known to be highly 
correlated to the exposure of tar and oxidant gases, Perez-Stable et al (1998) put
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forward the suggestion that this observation may explain why blacks are more likely to 
have higher smoking related risks of lung cancer and reproductive disorders compared 
to whites.
Caraballo et al (1998) have also reported that nicotine metabolism varies between 
populations, especially between non-Hispanic blacks and non-Hispanic whites or 
Mexican Americans. Their results suggest that serum cotinine levels are higher among 
non-Hispanic black smokers compared to non-Hispanic whites or Mexican American 
smokers. These differences in serum cotinine levels cannot be explained by reporting 
the number of cigarettes smoked or environmental tobacco smoke exposure, although 
they may be influenced by group-specific patterns of smoking behaviour and by 
differences in nicotine pharmacokinetics and brand mentholation, especially since more 
blacks (76 percent), compared to whites (23 percent) prefer mentholated cigarettes 
(Caraballo et al 1998). Mentholated cigarettes contain enough menthol to stimulate cold 
receptors, which simulates a “cool sensation”. This result in individuals unconsciously 
holding their breath, which allows for a greater transfer of inhaled tobacco smoke into 
the lung and pulmonary blood stream (http://www.goodhealth.freeservers.com).
Benowitz et al (1999) also reported that there were ethnic differences in the 
glucuronidation of nicotine and cotinine. Their findings suggested that blacks excrete 
significantly less nicotine as nicotine-iV-glucuronide and cotinine as cotinine-iV- 
glucuronide compared to whites, although there was no difference in the excretion of 3 '- 
hydroxycotinine-O-glucuronide
Nicotine metabolism has been reported to alter during pregnancy (Rebagliato et al 1998 and 
Dempsey et al 1998). Dempsey et al (1998) reported that CYP2A6 activity is enhanced 
during pregnancy, and this could lead to a greater tobacco consumption during 
pregnancy. Therefore, any nicotine therapy given to an expectant mother to help with 
smoking cessation would need to be altered to allow for the change in CYP2A6 activity. 
Dempsey et al (2002) also investigated nicotine metabolism in newborn babies. They 
collected blood samples during the first day of life for cotinine and nicotine analyses
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from 13 babies and daily urine samples from 9 of the 13 babies for up to 7 days to 
analyse for nicotine, cotinine, 3 '-hydroxycotinine and their glucuronides. All babies 
enrolled on the study were at risk of maternal cocaine use, but biological samples were 
only taken from babies whose umbilical cord plasma was negative for cocaine or 
metabolites but positive for cotinine.
The elimination half-life for nicotine and cotinine was 11.2 hours and 16.3 hours based 
on whole blood analysis, and 9.0 hours and 22.8 hours based on the urine analysis. The 
elimination half-life for nicotine glucuronide was 13 hours, for cotinine glucuronide
19.8 hours and 18.8 hours for 3'-hydroxycotinine glucuronide. Overall, the half-life for 
nicotine was three to four times longer in newborn babies than adults, whereas the half- 
life for cotinine was similar. They suggested that if the same enzymes were primarily 
responsible for the metabolism of nicotine, then it is unclear why the half-life should be 
different in newborn children and adults. However, it might be possible for a foetal- 
newborn form of CYP2A6 that has an altered affinity for nicotine but not cotinine 
(Dempsey et al 2002).
1.3.3 Phase II metabolism of nicotine
Phase II metabolites, are metabolites that have been further metabolised by an 
enzymatic transfer to a molecule or molecular substructure from an endogenous 
compound thus forming a metabolite with a higher molecular weight. These 
metabolites are often highly polar, water-soluble compounds which can aid the urinary 
excretion of foreign compounds and phase I metabolites. TV-Methylation, catalysed by 
methyltransferases and the formation of glucuronides are especially important phase II 
pathways in nicotine metabolism (Gorrod and Jacob 1999).
Curvall et al (1989) reported that the concentrations of nicotine and its metabolites, 
cotinine and trans-3 '-hydroxycotinine in urine samples taken from smokers and snuff 
users increased on average by a factor of 2.3 and 1.4, respectively when the urine 
samples were treated with p-glucuronidase. They interpreted this to mean that the
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observed increase in the concentration of nicotine and metabolites was due to the 
enzymatic cleavage of the respective glucuronides. They also reported that the 
glucuronides of cotinine and trans-3 '-hydroxycotinine were found in urine samples 
taken from non-smokers after oral administration of cotinine. Schepers et al (1992) 
reported that trans-3 '-hydroxycotinine glucuronide was the major phase II nicotine 
metabolite present in urine samples analysed in their study. Byrd et al (1992) 
confirmed that only nicotine, cotinine and trans-3 '-hydroxycotinine are excreted as 
glucuronides in smokers’ urine and that the glucuronides can account for up to 29 
percent of the total metabolites detected in urine from the individuals they studied. 
However, their results suggested that cotinine glucuronide was the major glucuronide 
excreted in urine.
The formation of the glucuronides of nicotine, cotinine and 3 '-hydroxycotinine is 
catalysed by UDP-glucuronosyltransferases (UGT), although the individual isozymes 
involved in 7V-glucuronidation of nicotine and cotinine and O-glucuronidation of trans- 
3 '-hydroxycotinine have not been identified (Gorrod and Jacob 1999). However, Benowitz 
et al (1994) suggested that the same UGT isozymes might be involved in the N- 
glucuronide formation of nicotine and cotinine, whereas a different UGT isozyme may 
be used for O-glucuronidation of trans-3 '-hydroxycotinine.
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1.4 Health effects associated with smoking
Inhaling tobacco smoke causes several immediate responses within the body. Once 
nicotine from the inhaled tobacco smoke reaches the small airways and the alveoli of 
the lung, it is buffered to physiological pH, where it can cross the cell membrane. 
Nicotine is rapidly absorbed into the blood stream, reaching the brain within 
approximately 10 to 20 seconds after smoking (Zevin et al 1998). Nicotine initially causes 
the release of adrenaline, an increase in blood pressure and heart rate. This effect may 
cause the heart rate to increase by as much as 30 percent during the first 10 minutes of 
smoking (Ash facts sheet no 6, 2002). Glucose is then released into the blood stream 
because of the increased levels of adrenaline. Nicotine can also block the release of the 
principal hyperglycaemic hormone, insulin, which prevents the excess glucose in the 
bloodstream from entering muscle and fat tissues. The smoker can then become 
hyperglycaemic, which may enable the brain to detect the excess sugar levels and down 
regulate hormones and other signals, causing an impaired appetite 
(http://www.howstufiworks.com).
Nicotine can cause a slight increase in the basal metabolic rate, enabling smokers to 
burn more calories. However, smokers tend to have an increased level of blood 
cholesterol compared to non-smokers, due to a lower ratio of high-density lipoproteins 
to low-density lipoproteins. Cigarette smokers have also been shown to have raised 
levels of fibrinogen and platelets, which may result in the smoker developing various 
forms of atherosclerotic disease. This may result in the arteries becoming more rigid 
and narrowed and it is more likely that the blood may form a thrombosis. The sudden 
blockage of an artery may lead to a fatal heart attack, a stroke or gangrene of the leg 
(Ash fact sheet no 6,2002).
Tobacco smoke also contains chemicals like carbon monoxide which reduces the
blood’s ability to carry oxygen as carbon monoxide can attach itself to haemoglobin
much more readily than oxygen, thus reducing the overall amount of oxygen available
to the tissues. The smoker can rapidly become tolerant to some of the side effects that
occur as result of smoking, such as, dizziness, nausea and vomiting. The tolerance to
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subjective effects and acceleration of heart rate can develop within a day in regular 
smokers (Benowitz et al 1998).
1.4.1 Diseases attributed to smoking
Smoking has been associated with a variety of health problems (Table 1.2), at least 80 
percent of all deaths from lung cancer, around 80 percent of all deaths from bronchitis 
and emphysema and 17 percent of all deaths from heart disease are caused as a result of 
smoking (Table 1.3) (Ash fact sheet no 2,2001).
In 1995, there were 46,000 cancer deaths (approximately a third of all cancers deaths) in 
the UK because of smoking (Ash fact sheet No 4, 2001). Cigarette smoking is the 
predominant cause of cancer of the lung, larynx, pharynx, oesophagus, bladder, kidney 
and pancreas and a 1996 review of cancers related to smoking concluded that cigarette 
smoking is also a cause of cancer of the lip (Ash fact sheet no 4,2001).
Enzymes induced by tobacco smoking may increase the risk of cancer by enhancing the 
metabolic activation of carcinogens (Zevin and Benowitz 1999). The risk of dying from 
lung cancer increases with the number of cigarettes smoked per day (Doll and Peto 1976) 
(Table 1.4) and it has been more recently reported to increase proportionally with the 
number of cigarettes smoked daily and the total number of smoking years (Thompson and 
Hunter 1998). Heavy smokers are at risk of up to 30 percent cumulative lifetime risk of 
developing cancer, compared to 1 percent for non-smokers (Thompson and Hunter 1998).
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INCREASED RISK FOR SMOKERS
Acute necrotizing ulcerative gingivitis (gum 
disease)
Muscle injuries
Angina (20 x risk) Neck pain
Back pain Nystagmus (abnormal eye movement)
Buerger’s disease (severe circulatory 
disease)
Ocular Histoplasmosis (fungal eye 
infection)
Duodenal ulcer Osteoporosis (in both sexes)
Cataract, posterior subcapsular (3 x risk) Osteoarthritis
Colon Polyps Penis (inability to have an erection)
Crohn’s disease (chronic inflamed bowel) Peripheral vascular disease
Depression Psoriasis (2 x risk)
Diabetes (Type 2, non-insulin dependent) Skin wrinkling (2 x risk)
Hearing loss Stomach ulcer
Influenza Rheumatoid arthritis
Impotence (2 x risk) Tendon injuries
Optic Neuropathy (loss of vision, 16 x risk) Tobacco Amblyopia (loss of vision)
Ligament injuries Tooth loss
Macular degeneration (2 x risk) Tuberculosis
FUNCTION IMPAIRED IN SMOKERS
Ejaculation (volume reduced) Sperm count reduced
Fertility (30% lower in women) Sperm motility impaired
Immune System (impaired) Sperm less able to penetrate ovum
Menopause (onset 1.74 years early on 
average)
Sperm shape abnormalities increased
SYMPTOMS WORS1E IN SMOKERS
Asthma Graves’ disease (over-active thyroid 
gland)
Chronic rhinitis (chronic inflammation of 
the nose)
Multiple Sclerosis
Diabetic retinopathy Optic Neuritis
DISEASE MORE SEVERE OR PERSISTENT
Common cold Pneumonia
Crohn’s Disease Tuberculosis
Influenza
Table 1.2 Summary of health problems associated with smoking (Ash fact sheet no 2,2001)
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ESTIMATED PERCENTAGES AND NUMBERS OD DEATHS ATTRIBUTED TO
SMOKING IN THE UK 
(BASED ON 1995 MORTALITY DATA)
Condition Percentage of deaths from 
the condition attributable 
to smoking in 1995
Number of deaths from the 
condition attributable to 
smoking in 1995
Men Women Men Women Total
CANCERS:
Lung 90 73 21,100 9,500 30,600
Throat and mouth 74 47 1,500 400 1,900
Oesophagus 71 62 2,900 1,600 4,500
Bladder 48 17 1,700 300 2,000
Kidney 41 5 700 100 800
Stomach 35 10 1,700 300 2,000
Pancreas 21 25 600 800 1,400
Unspecified site 34 7 2,400 500 2,900
Leukaemia 19 10 200 100 300
Total 46,400
HEART and 
CIRCULATION:
Ischaemic heart disease 23 11 18,700 7,600 26,300
Aortic aneurysm 62 48 4,000 1,800 5,800
Myocardial degeneration 24 10 300 300 600
Atherosclerosis 17 5 100 100 200
Stroke 13 9 3,400 3,900 7,300
Total 40,200
OTHERS:
Bronchitis and emphysema 86 79 15,100 9,300 24,400
Pneumonia 25 11 5,800 4,100 9,900
Ulcer of the stomach and 
duodenum
47 41 1000 1000 2,000
Total 36,300
Sub total 81,200 41,700 122,900
PREVENTABLE BY 
SMOKING*:
Parkinson’s 900 300 1,200
Cancer of the endometrium 100 100
Sub total 900 400 1,300
TOTAL 80,400 41,300 121,600
* Studies have shown that smoking appears to have a protective effect against the onset 
of some diseases such as endometrial cancer. However, the positive effect is so small in 
comparison with the overwhelming toll of death and disease caused by smoking that 
there is no direct public health benefit.
Deaths caused by smoking are six times higher than the 20,170 deaths arising from: road accidents 
(3,444); poisoning and overdose (2,663); other accidental deaths (8,986); murder and manslaughter (503); 
suicide (4,379); and HIV infection (195) in the UK during 1998 (Ash fact sheet 2,2001).
Table 1.3 Estimated number of deaths attributed to smoking (Ash fact sheet 2,2001).
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NUMBER OF CIGARETTES 
SMOKED PER DAY
ANNUAL DEATH RATE PER 100,000 
MEN
0 10
1-14 78 (8 times that of a non-smokers)
15-25 127 (13 times that of a non-smokers)
25 or more 251 (25 times that of a non-smokers)
Table 1.4 A study of male British doctors, deaths from lung cancer in smokers and non- 
smokers (Doll and Peto 1976)
Tobacco smoke contains a number of tobacco specific procarcinogen nitrosamines; for 
example A-nitrosodiethylamine, 4-(methylnitrosamino)-1 -(3 -pyridyl)-1 -butanone
(NNK) and A'-nitrosonomicotine (NNN). These compounds are termed pre- or 
procarcinogens because they are activated by the body to carcinogens. Carcinogens 
found in cigarette smoke through direct exposure, absorption, or transport through the 
body are also known to cause cancer of the pancreas, stomach, cervix, kidney and liver 
in addition to causing leukaemia (Thompson and Hunter 1998).
Each year, tobacco smoke accounts for around 26,000 deaths from coronary heart 
disease (CHD) in the UK, which is approximately 17 percent of all heart disease deaths 
(23 percent of deaths in men and 11 percent in women) (Ash fact sheet no 6,2002). The risk 
of a cigarette smoker of having a heart attack is two to three times that of a non-smoker. 
Doll and Peto (1994) reported than men under the age of 45 who smoke 25 or more 
cigarettes a day, were 15 times as likely to die from CHD as non-smokers of the same 
age. Even light smokers have an increased risk of developing CHD, and it has been 
reported that women who smoked 1-4 cigarettes a day had a 2.5-fold increase risk of 
fatal CHD (Bartecchi et al 1994).
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1.4.2 Smoking and pregnancy
Women who smoke may have reduced fertility. A study by Baird and Wilcox (1985) 
found that 38 percent of non-smokers conceived in their first cycle, compared to 28 
percent of smokers and that smokers were 3.4 times more likely than non-smokers taken 
more than one year to conceive. A recent British study found that smoking by men and 
both active and passive smoking by women were associated with delayed conception 
(Hull et al 2000). Fukuda et al (2002) found that the offspring ratio (male to female) was 
lower when either one or both parents smoked more than 20 cigarettes per day 
compared to couples were neither one smoked. The reason for the reduction in males is 
unclear, but it might be due to chronic exposure to toxic environmental agents, such as 
the toxins in cigarette smoke, that predominantly affect males and the male reproductive 
system. They also suggested that smoking reduced the offspring ratio around the time 
of conception, rather than imposing a selective disadvantage on male foetuses during 
later pregnancy.
Sasco and Vainio (1999) suggested that there is evidence that genotoxic and 
carcinogenic components of tobacco smoke can pass through to the placenta and the 
developing foetus. This is important since in western countries the highest or second 
highest group of smokers among women are of reproductive age (18-34 years old), and 
this may explain the increased awareness of the health effects linked to smoking in 
pregnancy (Sasco and Vainio 1999). About one-third of pregnant smokers quit smoking, 
the vast majority during the first trimester, although smoking cessation is dependent on 
several social factors and lone mothers, under-educated and less privileged ones are 
more unlikely to quit than better off women. A study carried out by Fingerhut et al 
(1990) found that 70 percent of women who quit smoking during pregnancy resumed 
smoking within 12 months. Their results also suggested that of the individuals, who 
resumed smoking, 67 percent resumed smoking within 3 months and 93 percent started 
smoking within six months of delivery.
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Babies bom to women who smoke are usually lighter, shorter and have a smaller head 
circumference. A study by Wang et al (1997) found that babies bom to continuously 
smoking mothers were on average, 257 g lighter, 1.2 cm shorter and 0.5 cm smaller in 
head circumference, compared to babies bom to non-smoking mothers. Babies bom to 
intermediate smoking mothers were on average, 56 g lighter in weight but they had 
similar birth length and head circumferences as babies bom to non-smoking mothers.
Becker et al (1999) measured urinary cotinine levels in 507 infants during the first two 
weeks of life and found that cotinine levels of infants from smoking mothers were 
significantly increased. Also breast-fed infants had higher cotinine levels than non­
breast-fed infants, but it was only significant (P<0.05) if the mother smoked. When 
they compared urinary cotinine levels of breast-fed infants whose mother smoked and 
infants whose mother smoked but did not breast-feed, the urinary concentrations were 5 
times higher in the breast-fed infants. This study highlighted the importance of 
encouraging mothers who smoke to give up, rather than discouraging them from breast­
feeding (Becker et al 1999).
A study carried out at Nottingham City Hospital compared data from 15,000 children 
bom during one week in 1970. Their findings were that almost 40 percent of children 
either exposed to tobacco smoke in the womb or soon afterwards displayed asthma 
symptoms by the age of 16. This compared to 29 percent of children who developed 
asthma but were not exposed to tobacco smoke (Ash asthma and smoking, 2002).
1.4.3 Environmental tobacco smoke
Environmental tobacco smoke (ETS) or passive smoking in the UK is thought to cause
several hundred cases of lung cancer and several thousand cases of heart disease in non-
smokers every year (Ash basic fact no 2, 2002). It has also been reported that people, who
are exposed to other people’s tobacco smoke, have suffered irritation of the eye, nose
and throat, reduced lung function in adults with no chronic chest problems and an
increase in the prevalence of cardiovascular disease. However, the health risks
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associated with ETS are small, compared to the risks associated with active smokers 
(Cummings et al 1990).
Biological samples taken from non-smokers have been shown to contain the 
constituents of ETS, which have been inhaled or absorbed by the non-smokers. A 
review of the literature by Zhong et al (2000) found that life-time non-smoking men and 
women experience a 48 percent and 20 percent excess risk of lung cancer respectively 
after being exposed to ETS from their spouses, and a 29 percent and 15 percent excess 
risk of developing lung cancer due to exposure to ETS at work. However, they also 
concluded that there was no evidence that exposure to ETS during childhood conferred 
a higher risk of lung cancer. Sasco and Vainio (1999) also carried out a review of the 
literature previously and suggested that there was no strong association between 
maternal smoking in pregnancy or exposure to ETS and cancer risk in childhood, 
although they did point out that their findings do not imply that tobacco use is not an 
issue.
Passive smoking also effects babies and children, and more than 17,000 children under 
the age of five are admitted to hospital every year because of the effects of passive 
smoking (Ash basic fact no 2, 2002). In children passive smoking can cause an increased 
risk of lower respiratory tract infection, increased severity of asthma symptoms, more 
frequent occurrence of chronic coughs, phlegm and wheezing, and increased risk of cot 
death and chronic middle ear effusion (glue ear).
Nafstad et al (1995) analysed nicotine concentrations in hair samples taken from 
children aged between 12 and 36 months. Questionnaires were also taken to enable 
information on the child’s ETS exposure to be determined. Compared to children 
registered as unexposed to ETS by the questionnaire, nicotine levels were 12.4 times 
higher among children who were exposed to more than 10 cigarettes per day and 3.4 
times higher among children exposed to between 1 and 10 cigarettes per day.
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Oddoze et al (1999) analysed urinary cotinine of children between 4 and 14 years old 
who reported a confirmed diagnosis or symptoms of asthma. Their results suggested 
that urinary cotinine concentrations and cotinine to creatinine ratio in children are 
highly correlated with the number of cigarettes the parents smoked. Their results also 
suggested that children had a higher concentration of cotinine if the mother only 
smoked compared to if the father only smoked. This may be linked to the mother taking 
on the responsibility of childcare.
1.5 Nicotine replacement therapy
Cigarette smoking is a highly addictive habit, involving both pharmacological and 
psychological addiction and the dependence on nicotine is reflected by the high failure 
rate among smokers who try to quit. Over 80 percent of smokers express a desire to 
quit, only 35 percent try to stop each year, and fewer than 5 percent are successful in 
unaided attempts to quit (Goodman and Gilman 1996).
The cost to the NHS for treating diseases caused by smoking is approximately £1.5 
billion a year. This amount includes the cost of hospital admissions, GP consultations 
and prescriptions. In 1997-98, 364,200 people were admitted to an NHS hospital to be 
treated for such diseases, occupying an average of 9,500 beds every day (Ash basic facts no 
3,2002).
Health care intervention to help with smoking cessation is very cost effective compared 
with many other treatments. For example the cost to the NHS of prescribing statins, 
drugs to lower cholesterol levels, is estimated to be between £5,400 and £13,300 per life 
year gained, whereas the cost of smoking cessation advice is estimated to range from 
£212 to £873 per life year gained (Ash basic facts no 3,2002).
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1.5.1 Smoking cessation
The health benefits for smokers who stop smoking compared to non-smokers have been 
reported to include a reduction in the overall risk of mortality 10-15 years after quitting, 
a reduction in the likelihood of suffering from coronary heart disease 2-4 years after 
smoking cessation and also a reduction in the possibility of developing all types of 
cancer after 10 years of abstaining from smoking (Thompson and Hunter 1998). Other 
health benefits include a decline in respiratory symptoms such as wheezing, coughing 
and phlegm production, which can be observed within 3 to 9 months after smoking 
cessation (Table 1.5) (Ash fact sheet no 11,2001).
TIME SINCE 
QUITTING
BENEFICIAL HEALTH CHANGES THAT TAKE
PLACE
20 minutes Blood pressure and pulse rate return to normal.
8 hours Nicotine and carbon monoxide levels in blood reduced by 
half, oxygen levels return to normal.
24 hours Carbon monoxide will be eliminated from the body. 
Lungs start to clear out mucus and other smoking debris.
48 hours There is no nicotine left in the body.
Ability to taste and smell greatly improved.
72 hours Breathing becomes easier.
Bronchial tubes begin to relax and energy levels increase.
2-12 weeks Circulation improves
3-9 months Coughs, wheezing and breathing problems improve as lung 
function is increased by up to 10%.
1 year Risk of a heart attack falls to about half that of a smoker.
10 years Risk of lung cancer falls to half that of a smoker.
15 years Risk of heart attack falls to the same as someone who has 
never smoked.
Table 1.5 Beneficial health changes that take place after abstaining from smoking
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For smoking cessation to work successfully, both non-pharmacological and 
pharmacological treatments are required, especially as the smoker can often associate 
smoking with certain activities, such as smoking at social events and after meals with 
coffee or alcohol (Thompson and Hunter 1998). Non-pharmacological treatments can 
include education, behavioural counselling, support groups, self-management, self­
monitoring, hypnosis and acupuncture (Thompson and Hunter 1998). However, White et al 
(2002) suggested that there is no clear evidence that acupuncture, acupressure, laser 
therapy or electrostimulation are effective for smoking cessation.
Nicotine replacement therapy is often used to alleviate nicotine withdrawal symptoms. 
Studies carried out by Henningfield et al (1995) have shown that this type of therapy 
can increase cessation rates by approximately two fold compared to placebo studies. 
The mechanism on how nicotine replacement therapy enhances smoking cessation is not 
completely understood, although it is believed that it enables relief of withdrawal 
symptoms by allowing the absorbed nicotine to bind to and desensitise nicotinic 
cholinergic receptors in the brain (Benowitz et al 1998). Benowitz (1993) reported that 
approximately 80 percent of individuals who typically smoke 10 or more cigarettes per 
day, exposing their body organs, including their brain, to nicotine 24 hours per day, who 
later abstain from smoking will experience withdrawal symptoms. Such withdrawal 
symptoms tend to occur as one or more symptom complexes; psychological distress, 
including irritability, anger, impatience and anxiety; difficulty concentrating, often 
associated with impaired cognitive performance, increased appetite, weight gain and 
tobacco craving (Table 1.6) (Ash fact sheet no 11,2001).
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WITHDRAWAL
SYMPTOMS
DURATION PERCENTAGE OF 
INDIVIDUALS WHO ARE 
TRYING TO QUIT BUT ARE 
AFFECTED
Irritability/ aggression Less than 4 weeks 50
Depression Less than 4 weeks 60
Restlessness Less than 4 weeks 60
Poor concentration Less than 2 weeks 60
Increased appetite Greater than 10 weeks 70
Light-headaches Less than 48 hours 10
Night-time awakenings Less than 1 week 25
Tobacco craving Greater than 2 weeks 70
Table 1.6 Percentage of individuals who are trying to quit but are affected by 
withdrawal symptoms (Ash fact sheet no 11,2001).
The main reason for nicotine replacement therapy is to aid an individual in breaking 
their addiction by relieving withdrawal symptoms; this then enables the individual to 
modify their life style in order to achieve permanent smoking cessation. Benowitz 
(1993) carried out a literature review into the chances of an individual quitting smoking, 
comparing the nicotine replacement patch to a placebo patch. The results from this 
review suggested that 39 percent to 71 percent of the individuals studied were able to 
quit smoking at 4 to 6 weeks, compared with 13 percent to 41 percent who used a 
placebo patch. By 6 months the number of individuals who were still not smoking were 
22 percent to 39 percent for the nicotine patch and 8 percent to 26 percent for the 
placebo patch. After one year the quit rates in the studies Benowitz (1993) looked at 
were 18 percent to 26 percent for nicotine patch versus 5 percent to 23 percent for 
placebo patch.
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Bohadana et al (2000) published a double blind, placebo-controlled trial using nicotine 
inhaler and nicotine patch as a combined therapy for smoking cessation. A combination 
therapy was chosen because they believed that it might increase cessation rates, 
compared to using a single replacement therapy. The trial was split into two groups, 
each consisting of 200 subjects who had smoked 10 or more cigarettes per day for 3 
years or longer. Group 1 subjects received the nicotine inhaler (10 mg) plus nicotine 
patch (delivering 15 mg of nicotine per 16 hours) for 6 weeks, then nicotine inhaler plus 
placebo patch for 6 weeks, then nicotine inhaler for 14 weeks. Group 2 subjects 
received the nicotine inhaler and placebo patch for 12 weeks, then the nicotine inhaler 
for 14 weeks. The inhaler could be used at a rate of 6 to 12 cartridges per day, ad 
libitum for 3 months before being tapered off.
Complete abstinence rates were then determined by carbon monoxide concentrations of 
less than 10 ppm and self reported smoking status. Complete abstinence rates at 6 
weeks were 60.5 percent for group 1 and 47.5 percent for group 2. By 12 weeks, the 
abstinence rates had dropped to 42.0 percent and 31.0 percent for groups 1 and 2 
respectively. At 6 months, the abstinence rates were 25 percent and 22.5 percent, 
dropping to 19.5 percent and 14 percent by 12 months for group 1 and 2 respectively. 
Overall, the results suggested that a therapy that combined the use of the nicotine 
inhaler and nicotine patch increased cessation rates, than if the inhaler was used alone.
Therefore, these results suggest that an individual is more likely to quit smoking with 
the aid of nicotine replacement therapy than unaided (Table 1.7). Even if an individual 
is unable to quit smoking altogether than nicotine replacement therapy can significantly 
decrease the number of cigarettes smoked.
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1.5.2 Nicotine replacement products
Nicotine replacement therapy is marketed as a variety of products, which include 
nicotine gum, patches (transdermal nicotine), nasal sprays and nicotine inhalers. 
However, nicotine cannot be taken orally, due to possible side effects that include 
indigestion and also it will be largely metabolised in the liver before reaching the 
systemic circulation (Tang et al 1994). Therefore, all nicotine replacement therapies are 
designed to enable nicotine to be directly absorbed into the systemic circulation through 
the buccal or nasal mucosa, the alveoli or skin (Tang et al 1994).
The first nicotine replacement product to be marketed was nicotine gum. Nicotine is 
attached in a loose association with the ionic bonding agent polarcrilex, to enable the 
controlled release of nicotine. After about 20 minutes of chewing, approximately 90 
percent of the available nicotine is released. Most of the nicotine is absorbed through 
the buccal mucosa and on average about a quarter is swallowed as saliva and 
metabolised but there is much variation between individuals (Tang et al 1994).
Nicotine replacement therapy is aimed at replacing nicotine that was previously 
consumed from their daily intake of tobacco, although for most individuals who are 
heavy smokers the amount of nicotine usually obtained from tobacco is not replaced by 
the therapy. Benowitz (1993) reported that for smokers who are more dependent on 
tobacco, then the average systemic intake of nicotine from cigarettes is approximately 
30 mg per day (comparable to approximately 30 cigarettes per day). However, if these 
individuals used nicotine gum on a fixed schedule of 10 to 12 pieces per day, then their 
plasma nicotine concentration averaged one to two thirds less than those seen in higher 
dependent cigarette smokers. However, some individuals would be able to match the 
nicotine concentrations achieved through smoking, although most do not. Therefore, 
smokers that are more dependent may require nicotine gum that has a higher level of 
nicotine for optimal results.
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QUITTING STRATEGY INCREASE IN QUITTING 
PERCENTAGE
Counselling and support
One to one advice (average 5 minute duration) 2
Counselling with follow-up (written, telephone, visit) 5
Minimal intervention strategy (MIS) 10
Group therapy 0-5
Behaviour therapy
General 2
Aversion No proven effect
Sensory deprivation No proven effect
Hypnosis No proven effect
Cutting down (reducing, changing brand) Little or no effect
Drug therapy
Nicotine substitutes (chewing gum, skin patches, 
inhalant, spray)
3-13
Zyban 11-15
Alternative therapy
Acupuncture No proven effect
Table 1.7 Overview of the most popular aids to quit smoking with their effectiveness in 
the long term (> 6 months). Results based on several studies, mainly biochemical 
monitoring (Berkmortel et al 2000)
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Nicotine skin patches release nicotine into the blood at a slow but constant rate. Three 
brands are licensed in Britain and are available over the counter. Two (Nicotinell and 
Nicabate) are worn for 24 hours, with three strengths corresponding to patch areas of 
30, 20 and 10 cm3, delivering 21, 14 and 7 mg of nicotine into the circulation over 24 
hours. One, Nicorette, is a 16 hour patch, removed at night, with three strengths, 15 mg, 
10 mg and 5 mg. Courses of about three months are recommended, beginning with a 
higher dose of patch and reducing at intervals.
The levels of nicotine in venous blood produced by transdermal nicotine patches, 
consisting of a dose of 21 mg/day, are 15 to 20 ng/ml, which is equivalent to the venous 
levels found in light smokers. Transdermal nicotine delivers nicotine to the systemic 
circulation in doses of 7 to 21 mg per day, depending on the patch and because nicotine 
is delivered over 16 to 24 hours, the peak concentration of nicotine during this time is 
considerably less than that seen while smoking (typically 20 to 40 pg/mL), although 
nicotine concentrations with the patch may exceed those seen in cigarette smokers 
overnight. However, the intake of nicotine from nicotine gum, nicotine nasal spray and 
nicotine inhalers on average delivers an even lower dose of nicotine than that observed 
with nicotine patches (Benowitz et al 1998).
Lawson et al (1998) carried out a study to determine the urinary excretion rates of 
cotinine and nicotine, to determine if a given dose of nicotine using nicotine 
replacement patches achieves 100 percent replacement. They concluded that for many 
individuals the amount of nicotine delivered using a standard 22 mg patch was 
significantly less than the amount obtained while smoking. Using nicotine excretion 
rate to calculate nicotine replacement showed that only 17 percent of subjects using the 
22 mg nicotine replacement patch achieved at least 100 percent replacement and when 
using cotinine excretion rates only 25 percent of subjects achieved 100 percent 
replacement (Lawson et al 1998).
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Nicotine nasal spray is absorbed through the nasal mucosa. This product might satisfy 
craving more effectively as it produces steady state plasma nicotine concentration 
similar to that from smoking, but the amount of plasma nicotine achieved is only over 
half that obtained from smoking a cigarette. The nicotine inhaler absorbs nicotine 
through the alveoli, as with cigarette smoking, but plasma nicotine levels achieved are 
even lower than the nasal spray (Tang et al 1994).
Recent advances have resulted in an alternative nicotine replacement therapy, bupropion 
chloride, otherwise known by its tradename, Zyban, which works by de-sensitising 
brain nicotine receptors. Bupropion chloride is a monocyclic antidepressant, 
structurally related to amphetamine, and was originally introduced as an antidepressant 
under the trade name, Wellbutin (Berkmortel et al 2000).
Gonzales et al (2001) carried out a double blind, placebo-controlled study in 450 
smokers who had previously used bupropion in a smoking cessation. Their study 
consisted of a screening phase, a 12 week treatment phase and a follow up after 6 
months. The primary aim of the study was to achieve continuous abstinence from 
smoking from weeks 4 through to 7. Their results suggested that 27 percent of 
participants who received bupropion SR remained abstinent throughout the four week 
period (weeks 4- 7), compared to 5 percent of participants who received a placebo. 
After 6 months 12 percent of participants who received bupropion SR abstained from 
smoking from week 4 to the follow up period after 6 months, compared to only 2 
percent of participants who received the placebo.
The results from clinical trials look promising that Zyban could be used as an alternative 
nicotine replacement therapy. However, for some adults it may not be safe to use as the 
estimated risk of the most serious side effect, seizures, is less than 1 in 1000 and less 
serious side effects have also been reported, which include, insomnia, dry mouth and 
headaches (Ash fact sheet no 11,2001). A recent publication by Tracey et al (2002) reported 
that in the initial 6 months after Zyban had been introduced to Ireland, there had been 
12 overdose cases reported to The Nation Poisons Information Centre, 8 patients
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developed symptoms of toxicity, whose symptoms included tachycardia, drowsiness, 
hallucinations and convulsions and 2 patients developed severe cardiac arrhythmias. 
One of the patients who developed a severe cardiac arrhythmia had to be resuscitated 
following a cardiac arrest. Tracey et al (2002) then further report that the potential toxic 
effect should be considered when prescribing Zyban as a smoking cessation aid.
Nicotine replacement therapy is not recommended by manufacturers to be used during 
pregnancy, due to the possible health risks to the foetus. However, smoking during 
pregnancy is harmful to the foetus and it is believed that nicotine may be one of the 
toxic components in tobacco that may contribute to foetal hypoxia and growth 
retardation through a reduction in placental blood flow (Tang et al 1994). Therefore, 
nicotine replacement therapy could have potential health risks to the unborn child, but 
they are likely to be less hazardous than moderate smoking, as nicotine replacement 
therapy produces a slower increase in plasma nicotine concentration, does not yield 
carbon monoxide or other noxious substances, and, if successful, does not expose the 
foetus to nicotine throughout pregnancy. Ideally, it would be in the interests of the 
unborn child, if the mother stopped smoking during the pregnancy without the aid of 
nicotine replacement therapy, but nicotine replacement may be justified if other 
methods fail.
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1.6 Analytical methods for the determination of nicotine and its 
metabolites
For many years individual smoking status has been determined using a variety of 
analytical methods to measure nicotine and its metabolites. The simplest method to 
determine if a person is a smoker or non-smoker, and to derive information regarding 
their smoking habits, is to use a questionnaire (Jarvis et al 1984, Cope et al 1996, Caraballo et al 
1998, Kharrazi et al 1999). The first questionnaire devised to measure nicotine addiction 
was the Fagerstrom tolerance questionnaire (FTQ) (Fagerstrom 1978) which was altered to 
become the Fagerstrom test for nicotine dependence (FTND) (Table 1.8) (Heatherton et al 
1991). The FTND questionnaire consists of 6 questions and a series of predetermined 
optional answers. Each answer is awarded a number of points, the sum total of these 
forms a score, which can determine the level of nicotine dependence.
For many years, questionnaires have provided information on individual smoking 
habits, and the information given has often been found to be incorrect compared to 
measurements taken in a laboratory (Sillett et al 1978, Wilcox et al 1979, Gillies et al 1982, Jarvis 
et al 1984, Peach et al 1985 and Nafstad et al 1995). Measurements using biological markers to 
determine the exposure to nicotine and multiple interviews regarding smoking habits 
over several years, suggest that 3 to 5 percent of smokers deny ever having smoked 
(Zhong et al 2000). A possible reason for this difference could be due to the attitude 
society has towards smoking; smokers are increasingly likely to underestimate their 
consumption of tobacco or even deny smoking altogether (Cope et al 1996). It is 
important, therefore, to be able to monitor patients attending a particular health clinic, 
such as smoking cessation or antenatal clinics, using quantitative or qualitative results. 
However, the only way to establish long-term exposure to nicotine is via questionnaires, 
as all other biological markers known are unable to account for long-term exposure to 
tobacco smoke (Zhong et al 2000).
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QUESTION ANSWER POINTS
1. How soon after you wake up do you smoke 
your first cigarette
Within 5 minutes 3
6 to 30 minutes 2
31 to 60 minutes 1
After 60 minutes 0
2. Do you find it difficult to refrain from 
smoking in places where it is forbidden, for 
example in church, at the library, in the 
cinema?
Yes 1
No 0
3. Which cigarette would you hate most to 
give up?
The first one in the 
morning 1
All of them 0
4. How many cigarettes per day do you 
smoke?
10 or less 0
11 to 20 1
21 to 30 2
31 or more 3
5. Do you smoke more frequently during the 
first hours after waking than during the rest of 
the day?
Yes 1
No 0
6. Do you smoke if you are so ill that you are 
in bed most of the day?
Yes 1
No 0
SCORING 0 to 2 Very low dependence
3 to 4 Low dependence
5 Medium dependence
6 to 7 High dependence
8 to 10 Very high dependence
Table 1.8 Fagerstrom test for nicotine dependence
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Nicotine is known to be the compound that establishes tobacco dependence, but this 
product only has a half-life of approximately two hours in serum, compared to cotinine 
which has a half-life of about seventeen hours in serum (Wall et al 1988). For this reason, 
nicotine is rarely used as a biological marker. Over the years alternative biological 
markers have been employed to determination smoking status, such as cotinine or 
compounds that are related to tobacco smoking, which have included thiocyanate (Hee et 
al 1995), carboxyhaemoglobin and carbon monoxide (Cope et al 1996 and Taniguchi et al 1999). 
However, the majority of analytical procedures use cotinine as the preferred biomarker 
of choice, due to its long half-life and it is also the primary derivative of nicotine. Other 
biological markers that have been used do not just represent an individual’s smoking 
habit as they can be detected in non-smokers. For example, thiocyanate is found in 
leafy green vegetables and carbon monoxide is found in traffic fumes. Therefore, it 
may be difficult to distinguish a light smoker and a non-smoker who is exposed to high 
levels of traffic fumes, resulting in a false positive result.
Vesey et al (1982) reported that self-reported cigarette consumption does not correlate 
to intake of nicotine since smokers can vary their intake of smoke by regulating the 
length and depth of inhalation or by the number and size of puffs and this is another 
reason why questionnaires differ from laboratory measurements. From their data they 
concluded that the measurement of either carboxyhaemogloblin or plasma thiocyanate 
concentrations is superior to self-reported cigarette consumption as an index of 
exposure to tobacco smoke.
Techniques used to measure smoking status have included colorimetric (Peach et al 1985, 
Barlow et al 1987 and Smith et al 1998), radiommunoassay (Langone et al 1973 and Knight et al 
1985), high performance liquid chromatography (HPLC) (Kyerematen et al 1982 and Moore et 
al 1990) and gas chromatography (GC) (Jacob et al 1981), using a samples taken from a 
variety of biological fluids, which include serum, saliva, urine and hair. Ideally samples 
used can be taken non-invasively, such as saliva, urine and hair, although hair samples 
have to be washed and pre-treated with sodium hydroxide overnight before cotinine 
analysis can be undertaken (Klein and Koren 1999). However, the advantage of using hair
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samples is that it is possible to determine tobacco exposure over a longer period than if 
other biological markers were used (i.e. serum, saliva and urine).
Each of the above techniques has it own advantages and disadvantages. The 
colorimetric technique is simple, cheap (less than 10 pence per test), and if determined 
qualitatively, then no laboratory equipment is required. However, this technique is has 
limited sensitivity and can not be used to measure small quantities or individual 
amounts of nicotine and its metabolites. The advantage of using radioimmunoassay is 
that it is an established method, and is often referred to as the “gold standard” for 
analysis of cotinine. This technique is more sensitive than the colorimetric methods and 
can detect serum nicotine levels of 6-8 ng/mL of serum. However, the disadvantage is 
that it uses radioactive isotopes, it can only measure one metabolite, usually cotinine, 
but cross over from other metabolites, such as nicotine and 3 '-hydroxycotinine, can 
occur.
Techniques like HPLC and GC can be more time consuming and require specialised 
equipment that can be expensive and is often only found in larger laboratories. Both 
HPLC and GC methods are more sensitive than the colorimetric technique, but to 
determine the small amounts of nicotine and its metabolites in environmental tobacco 
smoke then these techniques may be required to be coupled to a mass spectrometer. 
However, the advantage of HPLC and GC is that individual metabolites can be 
separated out, allowing metabolic profiles of the metabolism of nicotine to be studied.
1.6.1 High performance liquid chromatography techniques
HPLC techniques used to measure nicotine and its metabolites have included both UV 
(Zuccaro et al 1995 Nakajima et al 2000) and colorimetric methods of detection (Smith et al 1989, 
Moore et al 1990, Ubbink et al 1993, and Vindatiche et al 2000) using either pure nicotine or its 
metabolites or samples taken from biological fluids (for example urine, plasma or 
saliva).
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The investigation into nicotine pharmacokinetics requires a rapid, sensitive and reliable 
technique. Kyerematen et al (1987) reported such a technique using a radiometric 
HPLC assay for determining the concentration of nicotine and twelve of it metabolites 
in plasma and urine. Initial metabolic studies were performed on male Sprague-Dawley 
rats and each rat received a single 0.1 mg/kg dose of nicotine ([2-14C]pyrrolidine) 
containing 5 pCi. The mobile phase used was a binary gradient system consisting of 
solvent A: water: methanol: 0.1 M acetic acid buffer (pH 4.0): acetonitrile 
(187.5:11:1:0.5 v/v) and solvent B: water: methanol: 0.5 M acetic acid buffer (pH 4.0): 
acetonitrile (187.5:11:1:0.5 v/v) adjusted to pH 5.0 with triethylamine (0.10 percent, 
v/v).
Demetriou et al (1992) reported two radiochromatographic methods based on ion-pair 
HPLC and cation exchange HPLC. The reason why they chose radiometric detection 
was it enables the quantification of the known as well as the unknown nicotine 
metabolites on a molar basis. The two methods were then applied to investigate the 
metabolism of 2 '-14C-nicotine in rats’ urine. The ion-pair HPLC method determined 
more than 40 different radioactive peaks, 18 of which were identified by comparison 
with reference compound, and the ion exchange HPLC method detected the major 
nicotine metabolites.
Determination of nicotine and its metabolites using UV detection mainly consisted of 
isocratic HPLC techniques. Metabolites separated out successfully using this technique 
include nicotine, cotinine and 3 '-hydroxycotinine from urine samples (Zuccaro et al 1995), 
nicotine and cotinine from meconium samples (Baranowski et al 1998) and nicotine and 
cotinine either from urine samples (Oddoze et al 1998) or plasma samples (Nakajima et al 
2000). Ghosheh et al (2000) also used plasma samples but were able to separate cotinine 
glucuronide, 3'-hydroxycotinine glucuronide, 3 '-hydroxycotinine and caffeine as well 
as cotinine and nicotine. Cotinine glucuronide and 3 '-hydroxycotinine glucuronide 
were determined indirectly via basic hydrolysis. This involved adding sodium 
hydroxide to the plasma sample and heating at 70 °C for 30 minutes. The mixture was 
then extracted using dichloromethane, the organic layer centrifuged and the supernatant 
analysed.
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Seaton et al (1993) used a gradient HPLC method with UV detection to determine the 
concentration of nicotine 7V-glucuronide, cotinine iV-glucuronide and 3 '-hydroxycotinine 
in rat bile. The cotinine iV-glucuronide standard was synthesised by another group, 
nicotine iV-glucuronide was synthesised in house and 3 '-hydroxycotinine glucuronide 
was measured indirectly because it had not yet been synthesised. Overall, the 
glucuronide standards of cotinine and nicotine provided an alternative method for the 
measurements of such metabolites. It was also suggested that this method could allow a 
more thorough investigation of the pathways of nicotine metabolism than previously 
possible using the indirect method, i.e. treating samples with the enzyme P 
glucuronidase.
1.6.2 Gas chromatography techniques
Curvall et al (1982) described a rapid and sensitive method for the determination of 
nicotine and cotinine in plasma using capillary column gas chromatography with 
nitrogen-sensitivity detection using 7V-methylanabasine and iV-ethylnorcotinine as 
internal standards. The sensitivity and selectivity of the thermionic specific detector for 
nitrogen-containing compounds that they used allowed a relatively precise 
determination of small amounts of nicotine and cotinine. The detection limit at a signal 
to noise ratio of four was estimated to be 5 pg of nicotine and 20 pg of cotinine. The 
detector response was found to be linear and reproducible down to 5 pg of nicotine and 
20 pg of cotinine, which corresponds to a minimal detectable amount of 0.1 ng of 
nicotine and 0.4 ng of cotinine per mL of plasma. Calibration curves were determined 
between 5 and 100 ng for nicotine and between 5 and 500 ng for cotinine per mL of 
plasma using 1 mL and 0.1 mL samples.
Domino et al (1992) looked at two GC methods previously described (Hariharan et al 1991 
and Jacob et al 1991), a gas chromatographic-nitrogen specific detector (GC-ND) which 
had a column sensitivity of 10 pg for both nicotine and cotinine and a capillary gas 
chromatography-mass spectrometry (GC-MS) method. The capillary GC-MS method 
could simultaneously analyse both nicotine and cotinine using the corresponding
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deuterated compounds as internal standards and had a limit of detection of 1 ng/mL for 
nicotine and 10 ng/mL for cotinine. Domino et al (1992) reported that they had 
improved the sensitivity of the capillary GC-MS method to enable 10 pg/mL of nicotine 
and 50 pg/mL of cotinine to be determined, using non-deuterated internal standards. 
The mean inter-assay coefficient of variation for nicotine was 5 percent and for cotinine 
7 percent. Domino et al (1992) experience of nicotine and cotinine assays was limited 
to HPLC, GC-ND and GC-MS techniques. They suggested that HPLC is less expensive 
than the other two methods and is recommended for routine analysis. However, greater 
sensitivity can be achieved with GC-ND but for results that require high sensitivity and 
selectivity then they preferred to use GC-MS.
Baskin et al (1998) described a solid phase extraction method for determination of 
nicotine in serum and urine by isotope dilution GC-MS with selected ion monitoring. 
The method has a lower limit of determination of approximately 2 pg/mL and is linear 
to at least 2000 pg/mL. The within-run coefficients of variation were less than 4 percent 
for both assays over a nicotine concentration of 10-200 pg/mL. The between-run 
coefficients of variation in serum were 5.4, 5.2, 4.8 and 5.9, respectively, at nicotine 
concentrations of 10, 15, 25 and 50 pg/mL, and for the urine assays were 5.9, 4.5, 2.7 
and 5.2, respectively at nicotine concentrations of 100, 250, 500 and 2000 pg/mL. The 
absolute recovery of nicotine was 61± 6 percent (mean ± SD) over the range of 10-250 
pg/mL.
Jacob et al (1981) described an improved GC method for nicotine and cotinine 
determination that had been previously described (Langone et al 1973, Falkman et al 1975 and 
Feyerabend et al 1979). The internal standard used by the previous methods was quinoline 
but the results obtained in these studies were unable to be reproduced by Jacob et al 
(1981). They suggested that quinoline was a poor choice as nicotine is considerable 
more basic (jpK& 8.0) than quinoline (pK& 4.9) and synthesised a new internal standard 
N-ethylnomicotine, a structural analog with chemical properties similar to nicotine. 
They also improved the previously described extraction procedure for extracting 
cotinine from whole blood or plasma (Beckett 1966 and Hengen and Hengen 1978) by using 1-
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butanol instead of dichloromethane, which resulted in less emulsion forming and a 
cleaner separation of layers.
1.6.3 The Konig reaction
The colorimetric method (commonly known as the Konig reaction) used to detect 
urinary concentrations of nicotine and its metabolites, was first described by Peach et al 
in 1985 (further details on the Konig reaction are described in chapter 2). This method 
involves the addition of sodium acetate buffer, potassium cyanide, chloramine-T and a 
condensing reagent, barbituric acid, to a urine sample. Peach et al (1985) reported that 
when the condensing reagent, barbituric acid was used then red chromophores were 
formed, that were not extractable into ethyl acetate. On changing the condensing reagent 
to a less polar compound, diethyl thiobarbituric acid (DETB) they found that the 
chromophores produced were extractable into ethyl acetate. Using measurements taken 
from urine samples from 103 male smokers and 78 male non-smokers, they found that 
the false positive rate for the DETB chromophores extracted into ethyl acetate was 3 
percent, compared to 12 percent and 6 percent for DETB or barbituric respectively 
obtained when extraction was not carried out.
Barlow et al (1987) compared the quantitative direct barbituric acid (DBA) with a 
qualitative DBA method and an established cotinine radioimmunoassay (RIA). They 
used 128 reported smokers and 383 reported non-smokers. The quantitative DBA 
method results correlated with the RIA results, (r = 0.85), and coefficient of variation 
was 6 percent for the quantitative DBA method and 10 percent for the RIA method. 
Both the qualitative and quantitative DBA methods gave similar limits of detection rates 
of 91 percent and 93 percent, respectively, which corresponded to a false positive rate of 
3 percent.
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Barlow et al (1987) had also automated the quantitative DBA method, using a Flow 
Laboratories micronic tube system. This system increased sample throughput 
(approximately 170 samples per day), increased the speed at which the absorbance of 
each sample, within an analytical batch, could be measured (this was necessary since 
the coloured product is unstable, decaying at a rate of about 10 percent in 5 minutes) 
and also enabled a reduction in both sample and reagent volume. This method was 
reported to have an assay linear of at least 0-250 pmol/L cotinine.
Smith et al (1998) reported using the Konig reaction to measure urinary nicotine 
metabolites to assess smoking status in 251 diabetic subjects. Measurements were made 
qualitatively and quantitatively using DETB as the condensing reagent. Qualitative 
measurements were extracted into ethyl acetate and overall performance achieved a 
sensitivity of 95 percent and specificity of 100 percent. However, the quantitative 
results performed less well with a sensitivity of 92 percent and specificity of 97 percent.
The derivatives obtained from the Konig reaction have also been determined by various 
HPLC methods. O’Doherty et al (1990) used neat metabolites, 3-pyridyl acetic acid, 
trans-3 '-hydroxycotinine, cotinine, nicotine, A^-acetylnomicotine and demethylcotinine 
derivatized with either DETB or DMDD. Moore et al (1990) determined nicotine, 
cotinine and 3 '-hydroxycotinine in urine samples derivatized with DETB using a 
gradient HPLC method. Mariner et al (1992) studied an automated HPLC method using 
the analytical procedure described by Moore et al (1990) to study nicotine, cotinine and 
3 '-hydroxycotinine and treatment with P-glucuronidase in urine. Ubbink et al (1993) 
also used urine samples to separate out cotinine and nicotine but they used barbituric 
acid as the condensing reagent. Vindatiche et al (2000) optimised the conditions of the 
Konig reaction to enable nicotine and its metabolites cotinine, trans-3 '-hydroxycotinine 
and pyridylcarbinol to be measured in urine samples derivatized with thiobarbituric 
acid. Modifications included the addition of sodium hydroxide to the reaction mixture 
and then the reaction mixture was then centrifuged, the supernatant filtered and 
analysed but no time was stated to leave the reaction before analysis.
47
Chapter 2
The Konig reaction
2.1 Introduction
The Konig reaction was first described in 1904 (Konig 1904) and over the years has been 
used to measure compounds like cyanide, thiocyanate (Aldridge 1944) and derivatives of 
pyridine such as nicotinic acid (Leifer et al 1950 and Huebner 1951). More recently, this 
reaction was developed as a simple colorimetric test to measure urinary concentrations 
of isonicotinic acid and isonicotinylglycine, the major metabolites of the 
antituberculosis drug isoniazid (Ellard et al 1972). This test involves the sequential 
addition of sodium acetate buffer, potassium cyanide, chloramine-T and a condensing 
reagent, barbituric acid to a urine sample. During observations made whilst measuring 
urinary concentrations of isonicotinic acid and isonicotinylglycine, Peach et al (1985) 
reported that urine samples containing isonicotinic acid taken from non-smokers gave a 
characteristic blue colour, compared to urine samples taken from smokers not taking 
isoniazid, which gave a distinctive orange colour. The colour of the urine samples 
observed from smokers taking isoniazid was not reported, although it was later reported 
that the derivatives that formed the blue chromophores were not extractable in ethyl 
acetate (Ellard 1995). It was therefore suggested, that this orange colour could be due to 
nicotine and its metabolites.
Peach et al (1985) carried out a series of experiments using the Konig reaction and 
reported that this reaction could be used as a novel, simple and inexpensive urine test to 
determine smoking status. They also improved this reaction by changing the 
condensing reagent from the previously used condensing reagent, barbituric acid, to 1,3- 
diethyl-2-thiobarbituric acid (DETB), which forms pink-red chromophores, rather than 
orange and which are also readily extracted into ethyl acetate. The reason why they
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wanted to extract the pink chromophores into ethyl acetate was to increase the 
sensitivity of qualitative or semi quantitative measurements.
The chemistry involved in the Konig reaction when used in this way is not understood 
with certainty, although reaction mechanisms have been suggested by several groups 
(O’Doherty et al 1990 and Rustemeier et al 1993). Both workers proposed that the oxidising 
agent, chloramine-T first oxidises potassium cyanide to form cyanogen chloride. Once 
cyanogen chloride is produced, the pyridine ring of the nicotine metabolite is broken, 
which enables a condensing reagent (for example, barbituric acid or DETB) to react 
with the nicotine metabolite to form either structure 1 suggested by O’Doherty et al 
(1990) or structure 2, suggested by Rustemeier et al (1993) (figure 2.1).
It has been assumed that this reaction may be applied to the majority of the nicotine 
metabolites, and indeed is often referred to as a test for “total nicotine metabolites”. 
However, Rustemeier et al (1993) put forward the suggestion that only nicotine 
metabolites that contain an intact pyridine ring and also have no other atoms or groups 
attached to the nitrogen atom will react. Therefore, the majority of nicotine metabolites 
may be expected to undergo this reaction, with the exception of only a few metabolites 
such as cotinine-iV-oxide and the JV-glucuronides of cotinine and nicotine (figure 2.2).
49
Potassium cyanide + Chloramine-T
Cyanogen chloride +
N
Nicotine metabolite
H R
H-
0
O
'H
H H 
Glutacondialdehyde derivative
DETB 
( 2  moles)
A
Cyanogen chloride
H
HO
CN
DETB 
( 1  mole)
CN
S
Figure 2.1 Possible mechanisms for DETB derived nicotine metabolites as 
proposed by O’Doherty et al (1990) (1 ) and Rustemeier et al (1993) (2)
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OH
OHOH
OH
OHOH
Nicotine ^-glucuronide Cotinine A^-glucuronide
O
Cotinine N-oxide 
Figure 2.2 Structures of cotinine-A^-oxide and the A^-glucuronides
The Konig reaction may be used to measure nicotine metabolites present in a biological 
sample. For purposes of quantification the unknown sample is often standardised 
against a known concentration of cotinine and the result expressed as “cotinine 
equivalent”. However, there is no real reason why cotinine should be used, except that 
it has been thought to be the major nicotine metabolite and therefore has become the 
most commonly used marker for the assessment of exposure to nicotine. It would 
therefore be as justifiable to express the total nicotine metabolite concentration as 
nicotine or 3 '-hydroxycotinine equivalent concentrations rather than cotinine, although 
throughout this research cotinine equivalent concentrations have been used. Another 
reason why cotinine is used to determine nicotine exposure is due to its longer half-life 
of approximately 17 hours in serum, compared to nicotine which has a half-life of only 
2 hours in serum (Wall et al 1988).
51
The main aim of the work described in this chapter was to extend the study of the Konig
briefly at the relationship between the Konig reaction and certain nicotine metabolites, 
such as nicotine, cotinine and 3 '-hydroxycotinine (Smith and Cooke 1987, O’Doherty et al 
1990 and Rustemeier et al 1993). However, no other work has been reported or extended to 
include a larger range o f possible metabolites.
Detailed investigations of the Konig reaction were carried out using four condensing 
reagents (figure 2.3), l,3-diethyl-2-thiobarbituric acid (DETB), l,3-dibutyl-2- 
thiobarbituric acid (DBTB), 2,2-dimethyl-l,3-dioxane-4,6-dione (commercially known 
as Meldrum’s acid) (DMDD) and 2-methyl-2-(2-phenylethyl)-l,3-dioxane-4,6-dione 
(MPED).
reaction and its relationship to nicotine and its metabolites. Various studies have looked
O O
Et Bu
DETB DBTB
Me Me
DMDD MPED
Figure 2.3 Structures of the four condensing reagents
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Both DETB and DMDD have been used as condensing reagents in previous studies 
(Peach et al 1985 and O’Doherty et al 1990). However, when the coloured derivative produced 
using DETB or DMDD was extracted into ethyl acetate, it was observed that the colour 
was not fully extracted, although DETB derivatives appeared to be extracted more 
efficiently than when DMDD was used. Since DETB is less polar than DMDD, it was 
decided to synthesise the novel more non-polar condensing reagents DBTB and MPED 
in order to investigate the properties of derivatives obtained from these compounds.
The aim of synthesising these more non-polar condensing reagents was to try to 
improve the degree of extraction into organic solvent in order to enhance the overall 
sensitivity of the test. An increase in sensitivity might be expected to make qualitative 
assessment of smoking status more easily distinguishable between urine samples taken 
from smokers and non-smokers and therefore, might also reduce the number of samples 
misclassified, i.e. the number of false positives and false negatives. A result from an 
individual who is a smoker but is classified as a non-smoker by a diagnostic test is 
referred to as a false negative result, whereas false positive results refer to a non-smoker 
who is classified as a smoker by a laboratory test. Furthermore, if the Konig reaction 
could be further enhanced so as to sufficiently increase the overall assay sensitivity, 
allowing very small quantities of nicotine metabolites to be detected, then it might be 
possible to use this reaction as a simple means for determining the exposure to 
environmental tobacco smoke or to measure cotinine in samples other than urine, for 
example, saliva, where the concentration is considerably lower.
The only major nicotine metabolites that were not available for this research project 
were the glucuronides of cotinine, nicotine and 3 '-hydroxycotinine. One established 
method for the determination of the concentrations of glucuronides in a urine sample is 
to use the enzyme P-glucuronidase, an enzyme that cleaves the bond joining the 
carbohydrate residue to the nicotine-derived portion (Biyd et a 1992 and Rustemeier et al 
1993). The glucuronide can be either an O-glucuronide (3 '-hydroxycotinine) or an N- 
glucuronide (nicotine and cotinine) (figure 2.4). Once a urine sample has been treated 
with p-glucuronidase, the sugar residue is no longer associated with the nicotine-derived 
portion, enabling the metabolite to be measured using the Konig reaction. However, it is
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highly unlikely that the glucuronides, especially those of cotinine and nicotine, will 
react using the Konig reaction, and as there was no standard solution available to 
compare a concentration of a known glucuronide to an unknown urine sample the 
synthesis of cotinine iV-glucuronide was attempted.
CH3
OH
OHOH
OH
OHOH
Nicotine iV-glucuronide Cotinine 7V-glucuronide
O O" Y ^ O H  H 0 2C
Sr ch3
3'-Hydroxycotinine O-glucuronide
Figure 2.4 Structures of the O-glucuronide and iV-glucuronides
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2.2 Materials and methods
Potassium cyanide and chloramine-T were purchased from Merck BDH. N, JV-Dibutyl-
2-thiourea, 4-phenyl-2-butanone, diethyl malonate and Dowex 5 OX were purchased 
from Aldrich (Gillingham, UK). Amberlite XAD-4 was purchased from Fisher 
Scientific (Loughborough, UK). l,3-Diethyl-2-thiobarbituric acid, malonic acid, 
glucuronolactone, 30% hydrogen bromide in acetic acid and P-glucuronidase were all 
purchased from Sigma (Poole, Dorset. UK). Methanol, ethyl acetate and acetone were 
all general-purpose reagent grades. Nicotine metabolites nicotine, cotinine and 3- 
pyridyl acetic acid were purchased from sigma and nomicotine, norcotinine, 5'- 
hydroxycotinine, 4-3 -pyridyl-4-oxo-A-methyl butyramide, trans-3 '-hydroxycotinine, 4-
3-pyridyl-4-oxo butyric acid, cotinine-A-oxide and nicotine-1 A-oxide were a kind gift 
from Professor Peyton Jacob, USA. Absorbance readings were obtained using a Cecil 
9500 Super Aquarius. The NMR spectra were obtained using a Bruker AC 250.
2.2.1 Synthesis of l,3-dibutyl-2-thiobarbituric acid
l,3-Dibutyl-2-thiobarbituric acid was prepared according to the modified method of 
Hahn et al (1990). Sodium (6.5 g washed with petroleum spirits and dried) was placed 
in a round bottom flask containing methanol (75 mL). A, A-Dibutyl-2-thiourea (10 g, 
0.076 mol) and diethylmalonate (17.5 g, 0.1 mole) were added to the flask and the 
resulting reaction mixture was allowed to reflux for at least 36 hours. After this period 
water (50 mL) was added to the solution and partly evaporated under pressure to 
remove any remaining methanol. Any white precipitate (unreacted thiourea) which may 
have formed during evaporation was removed by filtration under reduced pressure. The 
solution was further diluted with water (100 mL), chilled on ice and then acidified with 
concentrated hydrochloric acid to a pH between 1 and 2. The resulting precipitate was 
collected and dried under reduced pressure producing a light yellow powder 1,3-dibutyl-
2-thiobarbituric acid (9.5 g). Melting point 56-60°C. *H NMR (250MHz; CDCI3) 5 
ppm 0.94 (6 H, t, J1.5, CH3x2); 1.35 (4H, m, CTLCTLCHA 1.6(4H, m, CH2CH2CH3); 
3.7 (2H, s, 0 =CCH2C=0 ); 4.3 (4H, t, J 7 .5 -NCH2CH2-)
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2 .2 . 2  Synthesis of 2 -methyI-2 - (2-phenylethyl)-l,3-dioxane-4, 6 -dione
To a mixture of malonic acid (13.5 g, 0.13 mol), acetic anhydride (16.2 g, 15 mL, 0.16 
mol) and concentrated sulphuric acid (0.5 mL) was added 4-phenyl-2-butanone (22.2 g, 
0.15 mol). The mixture was stirred at room temperature overnight and poured into 
water (200 mL) to afford an oil, which crystallised on standing. The solid product was 
filtered off, dried and recrystallised from ethyl acetate/ petroleum spirits to give 
colourless crystals (10.3 g, 34%). Melting point 82-84°C. ^ N M R  (250MHz; CDCI3) 8  
ppm 1.79 (3H, s, CH3); 2.26 (2 H, m, CH2); 2.80 (2 H, m, CH2); 7.28 (5H, m, ArH); 13C 
NMR (62.5 MHz; CDCI3) 5 ppm 26.31, 29.40, 36.58, 42.41, 107.60, 126.81, 128.66, 
129.04, 140.19, 163.47.
2.2.3 Attempted synthesis of cotinine-A-glucuronide
The attempted synthesis of cotinine A-glucuronide was carried out using a modified 
method as described by Caldwell et al (1992). The procedure involved using a four step 
synthesis (figure 2.5).
Step 1: Synthesis of methyl tetra-O-acetyl-P-D-glucopyranurate 4.
Glucuronolactone 3 (20 g) was stirred with methanol (155 mL) containing sodium 
hydroxide (55 mg) for 1 hour at ambient temperature. The methanol was removed 
under reduced pressure, keeping the bath temperature less than 50 °C. A mixture of 
acetic anhydride (75.5 mL) and pyridine (55 mL) was then added to the remaining 
residue. Note that when the acetic anhydride and pyridine solutions were added to the 
remaining residue, all solutions were pre-cooled on ice to ensure the temperature of the 
solution did not exceed 40 °C. The solution was then left overnight in the fridge to 
provide the solid product 4 (7.24 g). Melting point 168-176 °C, literature melting point 
(Caldwell etal 1992) 177°C.
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OHHO
OH
COOCH,
1. NaOH/MeOH AcO OAc
AcO AcO
H3C— N
O
o
IIAcO = C — CH3
4 °C HBr/AcOH
COOCH.
AcO(S)-(-)-Cotinine
AcO BrAcO
60 °C
lMNaOH
II6 COO 6 5
H O -^
(S)-(-)-Cotinine TV-glucuronide
H3C - n
Figure 2.5 Synthesis of A-P-D-glucopyranuronosyl-(s)-(-)cotininium inner salt (GA)a 
(cotinine A-glucuronide) (Caldwell et al 1992)
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Step 2: Synthesis of methyl 2,3,4-tri-O-acetyl-1 -bromo-1 -deoxy-a-D-glucopyranurate 5.
Compound 4 (7.24 g) was added to 30% hydrogen bromide in acetic acid (36 mL) and 
allowed to stand overnight at 4°C. The resulting residue was dissolved in 
dichloromethane (15 mL), and the organic solution extracted with saturated sodium 
bicarbonate solution (15 mL), followed by water (15 mL). The resulting 
dichloromethane layer was dried with magnesium sulphate and the solvent evaporated. 
The residue was crystallised from absolute ethanol to afford 5 as a cream-coloured 
crystalline solid (5.1 g). (Note this product readily decomposes if left at ambient 
temperature, and therefore it is best stored at - 2 0  °C). Melting point 74-78 °C, literature 
melting point (Caldwell etal 1992) 102-105°C. TLC ethyl acetate/ petroleum spirits 30:70 
Rf 0.80, (TLC plate developed with eerie ammonium sulphate). lK  NMR (250MHz; 
CDC13) 5 ppm 2.04-2.08 (9H, 3 x s, CH3COO); 3.75 (3H, s, COOCH3); 4.57 (1H, d, 
•710.2); 4.84 (1H, dd, 710.0, 4.0); 5.23 (1H, t, 710.0); 5.61 (1H, t, 79.7); 6.64 (1H, d, 
74.1).
Step 3: Synthesis of jV-(2,3,4-tri-0-acetyl-6-methyl-P-D-glucopyranuronosyl)-(S)-(-)- 
continium bromide 6 .
Compound 5 (2.37 g) was added to cotinine (0.2 g) and acetonitrile (10 mL) and 
refluxed under nitrogen for 4 days. The acetonitrile was removed under pressure. The 
resulting melt was partitioned between water and diethyl ether (5 x 20 mL). The 
aqueous layer was eluted through an XAD-4 column, followed by two bed volumes of 
distilled water. The aqueous layer was collected and the water evaporated under 
reduced pressure. From the NMR, it appeared that 6  had been synthesised, although 
impure, and therefore it was further purified on a silica column using 
dichloromethane/methanol 9:1 as the mobile phase. Once purified, the fractions 
containing 6  were evaporated under reduced pressure, leaving the solid product 6  (148 
mg). TLC dichloromethane/methanol 9:1, Rf 0.3. NMR spectrum before purification 
the following peaks were observed, *11 NMR (250MHz; CDCI3) 8  ppm 9.41-9.32 (m), 
8.81- 8.78 (d), 8.34-8.29 (t), 6.44 (d), 5.72-5.69 (d), 5.6-5.5 (m), 4.93-4.86 (m), 3.67 (s), 
2.29 (s), 2.14 (s), 1.86 (s), 1.78 (s) other peaks were also observed 3.36 (s), 2.50-2.54 
(m), 1.23-1.37 (m), 0.8-0.89 (m) which are believed to be solvent residues and 7.68-
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7.69 (m), 4.11-4.14(d), 3.9-3.93 (d) are believed to be impurities. NMR spectrum for 6 
(Caldwell et al 1992) !H NMR (DMSO-^4) 5 9.45-9.32 (2 H, m, pyridinium H-2 and H-6), 
8.84-8.80 (1 H, d, pyridinium H-4), 8.40-8.30 (1 H, t, pyridinium H-5), 6.40 (1 H, d, H- 
1"), 5.80-5.70 (2 H, m, H-2" and H-5'), 5.58-5.48 (1 H, t, H-4"), 4.83-4.95 (3 H, m, 
H-3", H-4' and H-5'), 3.70 (3 H, s, C 02CH3), 2.52 (3 H, s, NCH3), 2.23-2.43 (3 H, m, 
H-3'a, H-3'b and H-4'b), 2.12-2.20 (1 H, m, H-4'a), 1.8, 1.9, 2.1 (9 H, 3 X s, 3 X 
OCOCH3).
Step 4: synthesis ofiV-P-D-glucopyranuronosyl-(S)-(-)-cotininium inner salt 7
Compound 6 (148 mg) was dissolved in sodium hydroxide (1 mL, 1 M), and the 
solution was left at ambient temperature for 16 hours. The pH of the sample was then 
adjusted to 7.0 with dilute aqueous acetic acid, and the mixture was applied to a column 
containing strong cation-exchange resin (Dowex 50X 1, 50 -  100 mesh, 7 x 12 cm). 
The column was eluted with 4 bed volumes of distilled water, followed by 2 M aqueous 
ammonia solution. The first UV-absorbing basic fractions were collected and 
evaporated under reduced pressure but no significant amount of 7 was produced.
2.2.4 The Konig reaction
The Konig reaction, based on the method described by Peach et al (1985) was used to 
determine the total nicotine metabolite concentration in urine samples. The method 
involved taking a known concentration of an individual nicotine metabolite dissolved in 
distilled water (1 mL) or a neat urine sample (1 mL) and mixing with sodium acetate 
buffer (400 pL, 4 M, pH 4.7). This was then followed by potassium cyanide (200 \\L, 
10% w/v) and chloramine-T (200 |nL, 10%w/v). The solution was mixed well, before 
the addition of a condensing reagent (1 mL, 1% w/v, DBTB and MPED in acetone, 
DETB and DMDD 50:50 acetone: water). The reaction mixture was again mixed well 
and allowed to stand for 20 minutes.
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2.2.4.1 Qualitative or quantitative measurements of the Konig reaction
The Konig reaction can be used qualitatively or quantitatively. Qualitative 
determinations were made by a simple observation of a pink colour either in the 
aqueous layer or after extraction in ethyl acetate (1 mL). Quantitative measurements 
were determined either by measuring the absorbance of the aqueous layer (aqueous 
results) or of the organic layer after extraction with ethyl acetate (1 mL) (organic 
results), at the appropriate wavelengths. The spectrophotometer was set to zero using a 
sample blank, which was analysed following the method above except that chloramine- 
T was excluded.
An example is given below of the calculation to determine the concentration of a urine 
sample derivatized with DETB
Absorbance obtained from urine sample = 0.120
Absorbance obtained from cotinine (10 pg/mL) standard solution = 0.644
Absorbance of urine sample x concentration of cotinine 0.120 x 10 _  .
Absorbance of standard 0.644 ' ^
2.2.5 Relative molar absorptivity and partition coefficients
The relative molar absorptivity and partition coefficients for individual nicotine
metabolites were determined using the Konig reaction as in 2.2.4. When nicotine
metabolites were derivatized with either DETB or DBTB a 5 pg/mL stock solution was
used, except for 4-3-pyridyl-4-oxo methyl butyramide and trans-3 '-hydroxycotinine
where a 10 pg/mL stock solution was used and for 4-3-pyridyl-4-oxo butyric acid when
a 20 pg/mL solution was used. When metabolites were derivatized with either DMDD
or MPED, a 10 pg/mL solution was used for all relative molar absorptivities and
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partition coefficients. The absorbance maximum for each nicotine metabolite after 
being subjected to the Konig reaction was determined by measuring the absorbance 
between 400 nm and 700 nm. The absorbance of each nicotine metabolite was then 
measured, post derivatization, using the aqueous layer (aqueous results), organic layer 
(organic results) and the aqueous layer post extraction (post extraction aqueous results) 
at their absorbance maxima using each of the four condensing reagents (figure 2.6). 
Each nicotine metabolite was measured at least twice.
Aqueous
layer
•lmL of ethyl acetate
. Aqueous 
layer
-Organic layer
. Aqueous layer post 
extraction
Figure 2.6 Schematic diagram that represents the extracted and unextracted phases 
when using DETB or DBTB.
The absorbance values for each nicotine metabolite were obtained and appropriate 
calculations were carried out to determine both the relative molar absorptivity and 
partition coefficient. The relative molar absorptivity measurements were determined 
using the aqueous results, whereas the partition coefficients require the organic and post 
extraction aqueous results.
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The relative molar absorptivities were calculated using the Beer-Lambert Law,
A = sbc
Where A represents the absorbance, s is known as the molar absorptivity and is 
expressed as litres per mole per centimetre (L mol*1 cm'1), b represents the pathlength 
which is usually expressed in centimeters and c is the concentration of the sample in 
moles per litre.
Therefore, molar absorptivity, S =  A
be
An example of the calculation of relative molar absorptivity using cotinine derivatized 
with DETB.
RMM of cotinine = 176, pathlength = 1 cm 
Concentration of cotinine used = 5 pg/mL or 0.005 g/L
Molar concentration used:
concentration of cotinine 0.005 ___-------------m n ; ------------- = 2 . 8 4 x10RMM 176
However, the sample was diluted to 2.8 mL (total volume of reaction mixture)
Molar concentration 2 .84x10'5  s „Dilution factor = 1 .0 1 x 1 0  g/L
Average cotinine absorbance = 0.421
s = A 0.421 . , .£  l .O lT lO ^ x l =4.1 x 10 LM" cm
62
Partition coefficients were calculated using the following equation:
Partition coefficient, k =  As2
A si
Where As2 represents the absorbance obtained from the organic layer (solute 2) and Asi 
represents the absorbance obtained from the aqueous layer post extraction (solute 1).
An example is given below for the calculation of the partition coefficient using cotinine 
5 (j.g/mL derivatized with DETB
Average absorbance obtained from organic layer = 0.819
Average absorbance obtained from the aqueous layer post extraction = 0.140
A s2
Asi
0.819
0.140 =  6
2.2.6 Cotinine calibration curves
The aim of this experiment was to investigate the claim of Smith and Cooke (1987) that 
the Konig reaction does not follow the Beer-Lambert Law. Their findings suggested 
that the sum of the absorbance values obtained for three individual metabolites 
(nicotine, cotinine and nicotine-1'iV-oxide) were not the same as the predicted 
absorbance value when a mixture of the same three metabolites was used. From these 
results, they concluded that their results indicated that the Konig reaction significantly 
departs from the classical behaviour of the Beer-Lambert Law, which could have 
implications for the reliability of the method as a quantitative analytical tool.
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To determine if the Konig reaction followed the Beer-Lambert Law, calibration curves 
were prepared using pure cotinine dissolved in distilled water. The concentration of 
cotinine used for the calibration curves ranged from 4 pg/mL to 20 pg/mL. 
Measurements were taken at the optimum wavelength using all four condensing 
reagents. Each sample was measured in triplicate, and the results presented as the 
average absorbance.
2.2.7 Optimum reaction time courses
Smith and Cooke (1987) further suggested that the time required for the reaction to 
reach completion was unique to each of the compounds they investigated (nicotine, 
cotinine and nicotine-lW-oxide). In order to investigate this observation further 
individual reaction time courses were obtained using these three compounds and a 
further eight nicotine metabolites. Therefore, to determine the optimum time to leave 
the Konig reaction to measure the maximum total nicotine metabolite concentration, 
individual nicotine metabolite time courses were carried out. Once the Konig reaction 
(2.2.4) had been initiated with one of the four condensing reagents, the solution was 
mixed well and transferred into a cuvette. A spectrophotometer was set to record the 
absorbance values every four minutes, for a total of forty minutes.
2.2.8 Imprecision studies
Imprecision measurements were made using a “pooled” urine sample taken from five 
confirmed smokers. The pooled urine sample was subdivided into ten aliquots (1 mL) 
and each aliquot was subjected to the Konig reaction (2.2.4) using each of the 
condensing reagents. The concentration of each aliquot was determined by comparison 
with the absorbance value obtained from a cotinine (10 pg/mL) standard solution and 
the coefficient of variation calculated.
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2.2.9 Determination of the effects of P-glucuronidase
Byrd et al (1992) described a method to quantify the glucuronide concentration of 
cotinine, nicotine and 3 '-hydroxycotinine in urine samples by treating the sample with 
the enzyme P-glucuronidase. Modifications were made to this method in order to 
determine the optimal amount of P-glucuronidase required. A urine sample (10 mL) 
was taken from a self-reported smoker and adjusted to pH 5.0 with 4 M hydrochloric 
acid (0.5 mL). An aliquot of this sample (1 mL) was taken and a known amount of p- 
glucuronidase was added. The sample was then incubated at 37°C for approximately 
twenty-four hours. To determine the optimum amount of P-glucuronidase, different 
amounts of the enzyme were prepared between 500 IU and 1500 IU (table 2.1). This 
range was chosen because Byrd et al (1992) had used 3650 IU of P-glucuronidase per 3 
mL or 1216.7 IU per mL.
Calculations to decide the amount of P-glucuronidase required were carried out using 
the following equation.
 Number of IU required per mL________  = amount required in pL
IU of stock solution of P-glucuronidase per pL
IU of P-glucuronidase per mL (obtained from label on the P-glucuronidase bottle) 
= 89400 IU/mL or 89.4 IU/ pL
For example: 1000 _
Amount required for 1000 IU 89.4 ^
For ^ampler 89.4 x 13.5 = 1206.9 IU/mL of urineNumber of IU in 13.5 pL
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IU REQUIRED 
PER ML OF 
URINE
pL REQUIRED 
PER ML OF 
URINE
ACTUAL pL 
USED PER ML OF 
URINE
ACTUALIU 
USED PER ML 
OF URINE
500 5.59 6 536.4
750 8.39 8 715.2
1000 11.19 11 983.4
1200 13.42 13.5 1206.9
1500 16.79 17 1519.8
Table 2.1 Required amount P-glucuronidase used to determine optimal concentration
After a twenty-four hour incubation, the urine samples were subjected to the Konig 
reaction (2.2.4) using DBTB as the condensing reagent. Absorbance measurements 
were carried out in duplicate at 525 nm, using the aqueous layer and the cotinine 
equivalent concentration of each sample was determined using the absorbance value 
obtained from a cotinine (10 pg/mL) standard solution.
Further studies using P-glucuronidase were carried out to determine if the cotinine 
equivalent concentration after treatment with P-glucuronidase increased significantly 
more in urine samples taken from self-reported smokers, compared to urine samples 
taken from self-reported non-smokers. Urine samples were taken from five smokers 
and five non-smokers. Each urine sample (30 mL) was split into three aliquots (10 mL 
each). The first aliquots (batch one) of urine samples were adjusted to pH 5.0 and 1 mL 
of urine was then transferred to a second container, where the addition of the enzyme P- 
glucuronidase (10 pL, 894 IU) occurred. The samples were then placed in a water bath 
and incubated at 37°C. The first batch is the only batch of urine samples that had the 
enzyme added, although a further two batches were used as controls to ensure that the 
temperature of the water bath or changing the pH of the urine sample had no effect on 
the total nicotine metabolite concentration. The second aliquots (batch two) of urine 
samples were placed in the water bath alongside those from batch one. The third 
aliquots (batch three) of urine samples were adjusted to pH 5.0 and placed in the water 
bath. After approximately twenty-four hours, all urine samples were removed from the
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water bath and the total nicotine metabolite concentrations were measured using DBTB 
as the condensing reagent. Measurements were carried out at 525nm using the aqueous 
layer.
2.3 Results and discussion
2.3.1 Relative molar absorptivities and partition coefficients
Relative molar absorptivities for each individual nicotine metabolite post derivatization 
using either DETB or DBTB are shown in table 2.2. The relative molar absorptivities 
for nicotine metabolites derivatized using DETB range from 0.55 x 104L M '1cm‘1 for 4-
3-pyridyl-4-oxo butyric acid to 4.1 x 104 L M'1cm‘1 for cotinine, whereas nicotine 
metabolites derivatized using DBTB range from 0.46 x 104 L M‘1cm'1 for 4-3-pyridyl-4- 
oxo butyric acid to 5.2 x 104 L M'1cm'1 for cotinine. Overall, the relative molar 
absorptivities were higher when the condensing reagent DBTB was used, compared to 
DETB, although 4-3-pyridyl-4-oxo butyric acid appeared to be the exception.
Cotinine-JV-oxide was the only nicotine metabolite that produced a solution of 
insufficient colour to measure either the relative molar absorptivity or partition 
coefficient. This is in accordance with the predictions of Rustemeier et al (1993) who 
suggested cotinine-N-oxide would be one of the few metabolites that would be unable 
to undergo the Konig reaction, due to an oxygen atom being attached to the nitrogen 
atom situated in the pyridine ring (figure 2.2).
Relative molar absorptivities for nicotine metabolites derivatized with either DMDD or 
MPED are shown in table 2.3. The relative molar absorptivities obtained using the 
condensing reagent DMDD, ranged from 0.8 x 104 L M'1cm'1 for 3-pyridyl acetic acid 
to 4.4 x 104 L M^cm'1 for cotinine, compared to nicotine metabolites derivatized using
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DBTB MOLAR 
ABSORPTIVITIES x 
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MPED which range from to 1.7 x 104 L M^cm'1 for 3-pyridyl acetic acid to 4.0 x 104 L 
M^cm'1 for cotinine.
The relative molar absorptivities for MPED were not always higher than DMDD and 
therefore cannot follow the same trends as for the relative molar absorptivities obtained 
using DETB and DBTB. If MPED had followed the same trend as DBTB, then it 
would have been expected that MPED, being the more non-polar condensing reagent 
compared to DMDD, would have had higher relative molar absorptivities.
The nicotine metabolite, 4-3-pyridyl-4-oxo butyric acid produced no significant 
absorbance when the condensing reagents DMDD or MPED were used to determine the 
relative molar absorptivity or partition coefficient. One possible reason could be that 
the relative molar absorptivities for 4-3-pyridyl-4-oxo butyric acid using DETB or 
DBTB were low and therefore, if 4-3-pyridy 1-4-oxo butyric acid does not react as 
readily with DMDD or MPED then the absorbance value may fall just below the limit 
of detection.
The maximum wavelength used to determine the absorbance of the derivative also 
slightly varied depending on the nicotine metabolite and condensing reagent used, 
although for the majority of nicotine metabolites the maximum wavelength was 
between 531nm and 533 nm.
Each nicotine metabolite, post derivatization, had its own relative molar absorptivity, 
which varied depending on the condensing reagent used and similar trends for all four 
condensing reagents were generally followed. For example cotinine always had the 
highest relative molar absorptivity and 4-3 pyridyl-4-oxo-butyric acid and cotinine-iV- 
oxide had the lowest molar absorptivity. However, when the molar absorptivities for 
each nicotine metabolite were ranked from the highest to lowest molar absorptivity for 
each condensing reagent (table 2.4), it was determined that not all nicotine metabolites 
were ranked in the same order for each condensing reagent.
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For example 5 '-hydroxycotinine was ranked sixth using DETB or DBTB but third when 
DMDD or MPED were used.
The molar absorptivities using DETB or DMDD have been previously reported (Smith 
and Cooke 1987 and O’Doherty et al 1990). Smith and Cooke (1987) reported that the three 
nicotine metabolites cotinine, nicotine and nicotine-1'iV-oxide, derivatized with DETB, 
gave molar absorptivities which ranged from 1.3 x 104 L M'1cm'1 for nicotine-1 W-oxide 
to 3.1 x 104 L M^cm'1 for nicotine. The results obtained in this study agree with the 
results obtained by Smith and Cooke (1987), except for cotinine which had a higher 
molar absorptivity than nicotine in this study but was reported to have a molar 
absorptivity less than nicotine by Smith and Cooke (1987).
One possible reason why the molar absorptivities differ in these two studies is that 
Smith and Cooke (1987) measured all the derivatized nicotine metabolites at 536 nm, 
whereas in this current study each nicotine metabolite was measured at the appropriate 
wavelength. In this study cotinine derivatized with DETB was measured at 525 nm and 
therefore it may be possible that when the derivative of cotinine was measured by Smith 
and Cooke (1987) at 536 nm, the reaction was not measured at the maximum 
absorbance, which would result in a lower molar absorptivity.
O’Doherty et al (1990) also looked at the molar absorptivities for the four nicotine 
metabolites; cotinine, nicotine, trans-3 '-hydroxycotinine and 3-pyridyl acetic acid 
derivatized with either DETB or DMDD. They also concluded that each metabolite had 
its own molar absorptivity and that the metabolites derivatized with DETB gave a molar 
absorptivity which ranged from 4.4 x 104 M^cnT1 for 3-pyridyl acetic acid to 7.0 x 104 
M^cm'1 for cotinine, whereas the metabolites derivatized with DMDD ranged from 5.7 
x 104 M^cnT1 for 3-pyridyl acetic acid to 7.7 x 104 M^cm'1 for trans-3 
hydroxycotinine. Overall, the nicotine metabolites derivatized with DMDD had a 
higher molar absorptivity, compared to the same nicotine metabolites derivatized with 
DETB.
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The DETB results published by Smith and Cooke (1987) are very similar to DETB 
results obtain in this current study. However, the results obtained by O’Doherty et al 
(1990) are significantly higher for the nicotine metabolites derivatized with either 
DETB or DMDD compared to Smith and Cooke (1987) or this current study. A 
possible reason for the differences in the molar absorptivities is that this current 
research investigated the relative molar absorptivities; absorbance measurements were 
obtained using the crude reaction mixture, rather than isolating the derivatized 
metabolite to give a true molar absorptivity. O’Doherty et al (1990) used a solid phase 
extraction cartridge (Cig) to remove any undesirable matrix components, leaving the 
purified derivatized nicotine metabolite to be eluted from the column.
The reason why the true molar absorptivities were not studied is that it is very difficult 
to isolate the derivatized nicotine metabolites in a pure form that can then be accurately 
weighed to give a known concentration. The relative molar absorptivities will more 
realistically reflect the situations used in everyday analysis as it would be extremely 
difficult to purify the nicotine metabolites present in a biological sample such as urine. 
Also the sources and the relative purities of the nicotine metabolites are unknown and 
so it was decided to study the relative molar absorptivities of each nicotine metabolite.
The importance of these findings is that the absorbance obtained from an unknown 
biological sample, for example urine, may be compiled from different contributions of 
individual nicotine metabolites depending on an individual nicotine metabolic profile. 
This then has further implications when determining the true concentration of individual 
nicotine metabolites by analytical techniques like HPLC.
The partition coefficients for nicotine metabolites derivatized with either DETB or 
DBTB are shown in table 2.5. Overall, the results obtained suggest that nicotine 
metabolites derivatized DBTB partition slightly more efficiently than nicotine 
metabolites derivatized with DETB, except for cotinine and nicotine. The partition 
coefficients for nicotine metabolites derivatized with DETB range from 5 to 10, 
compared to metabolites derivatized with DBTB which ranged from 4 to 10.
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NICOTINE METABOLITE 
(CONCENTRATION pg/mL)
DETB
PARTITION
COEFFICIENT
DBTB
PARTITION
COEFFICIENT
Cotinine (5) 6 4
Nicotine (5) 9 7
Norcotinine (5) 5 10
Nomicotine (5) 9 9
5 '-Hydroxycotinine (5) 5 8
4-3-Pyridyl-4-oxo butyric acid (20) 6 5
Trans-3 '-hydroxycotinine (5) 5 8
3-Pyridyl acetic acid (10) 5 7
4-3-Pyridyl-4-oxo-jV-methyl butyramide (10) 5 10
Cotinine-iV-oxide No reaction No reaction
Nicotine-1 W-oxide (5) 10 5
Table 2.5 Partition coefficients for nicotine metabolites derivatized with either DETB 
or DBTB
The partition coefficients for nicotine metabolites derivatized with either DMDD or 
MPED are shown in table 2.6. Nicotine metabolites derivatized with DMDD ranged 
from 1 to 4, compared to nicotine metabolites derivatized with MPED, which ranged 
from 12 to 32.
NICOTINE METABOLITE DMDD MPED
PARTITION PARTITION
COEFFICIENT COEFFICIENT
Cotinine (10) 1 23
Nicotine (10) 3 12
Norcotinine (10) 1 19
Nomicotine (10) 3 32
5 '-hydroxycotinine (10) 2 22
4-3-Pyridyl-4-oxo butyric acid No reaction No reaction
Trans-3 '-hydroxycotinine (10) 1 17
3-Pyridyl acetic acid (10) 1 18
4-3 -Pyridyl-4-oxo-Af-methyl butyramide (10) 2 23
Cotinine-jV-oxide No reaction No reaction
Nicotine-1 W-oxide (10) 4 32
Table 2.6 Partition coefficients for nicotine metabolites derivatized with either DMDD 
or MPED
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The results show that when the more non-polar condensing reagent, MPED, was used, 
there was a significant increase in the relative partitioning coefficients compared to the 
other condensing reagents. The increase in the relative partition coefficient suggests 
that MPED has the potential to increase the sensitivity of the total nicotine metabolite 
concentration and therefore may prove to be a more suitable condensing reagent when 
carrying out analytical methods such as HPLC.
2.3.2 Cotinine calibration curves
Calibration curves for the absorbance produced by cotinine are shown in figures 2.7 to 
2.10. The results indicate that cotinine derivatized with any of the four condensing 
reagents overall produces a curve, rather than a continuous straight line over the 
concentration range chosen. However when cotinine is derivatized with either DETB, 
DMDD or MPED a straight line is produced between 0-8 pg/mL (0-0.045 |imol/L), 
which indicates that the Konig reaction does follow the Beer-Lambert law, i.e. that the 
absorbance is proportional to concentration between these two values. For cotinine 
derivatized with DBTB a straight line is produced between 4-12 fig/mL (0.023-0.068 
pmol/L), suggesting that the Beer-Lambert law is obeyed between these two values.
However, Pickert et al (1993) verified the linearity of the Konig reaction by using a 
cotinine equivalent urine sample by dissolving cotinine (25 mg) in a non-smoker urine 
sample. They produced a calibration curve from 2.5 to 250 mg/L and found that the 
reaction was linear up to 100 mg/L. One possible reason why these results differ from 
the current study is that Pickert et al (1993) determined the linearity of the reaction 
using a urine sample spiked with cotinine, whereas the current study used pure cotinine.
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Figure 2.7 A standard curve for the absorbance produced by cotinine using DETB
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Figure 2.8 A standard curve for the absorbance produced by cotinine using DBTB
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Figure 2.10 A standard curve for the absorbance produced by cotinine derivatized with 
MPED
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Smith and Cooke (1987) reported that when they measured the absorbance of a mixture 
of cotinine, nicotine and nicotine 1 W-oxide, the absorbance values obtained were lower 
than anticipated compared to the total sum of the absorbance values for each individual 
metabolite. They also suggested that this “indicated that the Konig reaction had grave 
implications for the reliability of the method as a quantitative analytical tool”. 
However, a likely reason why Smith and Cooke (1987) observed a lower absorbance 
value for a mixture of metabolites, compared to the same metabolites measured 
individually, is that although the mixture contains the same concentration of individual 
metabolites, overall the mixture has a higher total nicotine metabolite concentration. 
Therefore, the mixture will contain more molecules, and the more molecules a solution 
contains then the greater the chance that certain molecules will form weak interactions 
with each other. If a molecule is interacting with another molecule then it is unable to 
be excited by the light energy, and this can than produce a lower absorbance value 
compared to when the same number of molecules are measured individually and their 
absorbance values grouped together.
2.3.3 Optimum reaction time course
The time for the reaction to reach completion for each nicotine metabolite derivatized 
with each of the condensing reagents is shown in figures 2.11 to 2.14. The results 
observed by Smith and Cooke (1987) suggest that nicotine and its metabolites, cotinine 
and nicotine-1'iV-oxide derivatized with DETB had their own time course. Nicotine 
took 90 minutes to reach its maximum absorbance before the absorbance declined, 
whereas for cotinine the colour developed rapidly and then remained stable for at least 2 
hours, while the colour for nicotine-1 W-oxide developed rapidly, reaching a maximum 
absorbance within 2 minutes but sharply declined and after 20 minutes there was 
approximately a 30 percent loss of absorbance. As a result of the different time courses 
obtained, Smith and Cooke (1987) adopted 20 minutes as a standard waiting period due 
to operator convenience, although they could have chosen 2 minutes for nicotine-1W- 
oxide or 90 minutes for nicotine.
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Figure 2.11 Reaction time course for nicotine metabolites derivatized with DETB
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Figure 2.12 Reaction time course for nicotine metabolites derivatized with DBTB
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Figure 2.14 Reaction time course for nicotine metabolites derivatized with MPED
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The results in this study confirmed that each nicotine metabolite has its own reaction 
time course and that each nicotine metabolite reacts slightly differently. Some nicotine 
metabolites reach their absorbance maximum in the first ten to twenty minutes and then 
start to decline, whereas with other nicotine metabolites absorbance steadily increases 
over the entire forty minutes of the experiment. However, the time courses for cotinine, 
nicotine and nicotine-l'/V-oxide from this study were not the same shape as reported by 
Smith and Cooke (1987). The reason for this may be that this current study observed 
the absorbance using the aqueous layer, whereas Smith and Cooke (1987) determined 
the absorbance values once extracted into ethyl acetate. Nonetheless, it can be broadly 
concluded by both studies that twenty minutes is the most appropriate reaction time.
2.3.4 Imprecision studies
Imprecision studies were carried out using a “pooled” smoker’s urine sample. The 
within batch imprecision results obtained for DETB was 5.84 percent, DBTB 5.95 
percent, DMDD 8.63 percent and MPED 9.92 percent. The results indicate that all 
condensing reagents used had an acceptable imprecision value but when derivatized 
with either DETB or DBTB imprecision was slightly better than with DMDD or MPED. 
A major contributor to imprecision is the use of multiple steps and therefore one way of 
improving the overall precision of the reaction would be to reduce the number of steps 
involved or to automate the Konig reaction.
Various studies have used the Konig reaction to measure nicotine and its metabolites 
(Peach et al 1985, Smith and Cooke 1987, Smith et al 1989, O’Doherty et al 1990, Phillipou et al 1994 
and Smith et al 1998) but only two studies that had automated this reaction published 
imprecision data (Puhakainen et al 1987 and Pickert et al 1993). Puhakainen et al (1987) 
reported an imprecision of 6.8 percent for 13.6 fimol/L urine pool and 3.4 percent for
39.2 pmol/L using a continuous flow auto-analyser with barbituric acid as the 
condensing reagent. Pickert et al (1993) reported that their automated Konig reaction 
using DETB and a Cobas-Fara II analyser had a within assay imprecision of 4.3 percent 
for 41.6 mg/ and 5.2 percent for 2.8 mg/L cotinine equivalent in urine and a between
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assay imprecision of 8.6 percent for 39.3 mg/L and 16.4 percent for 1.9 mg/L cotinine 
equivalent in urine.
2.3.5 Determination of the effects of P-glucuronidase
The synthesis of cotinine A^-glucuronide was attempted, although no significant yield of 
7 (cotinine iV-glucuronide) was produced, despite several attempts with various 
modifications. After Caldwell et al (1992) were consulted about their publication on the 
synthesis of cotinine iV-glucuronide, it become apparent there was some ambiguity 
about the method they had actually used in the final step of the synthesis, and this was 
confirmed later after a publication was found describing a modified procedure by the 
same group (Crooks et al 1992). Due to the time already spent investigating the various 
steps and waiting for correspondence from Caldwell et a l , it was decided not to carry 
on with the synthesis of cotinine N-glucuronide.
The enzyme P-glucuronidase was used to determine the contributions that the 
glucuronides make to the total nicotine metabolite concentration in urine samples taken 
from self-reported smokers and non-smokers. The optimum amount of P-glucuronidase 
to use was determined from the standard curve to be 900 IU or lOfiL (figure 2.15).
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Figure 2.15 Determining the optimum concentration of P-glucuronidase
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The absorbance measurements obtained from the urine samples from self-reported 
smokers and non-smokers were converted to cotinine equivalent concentrations. The 
results from the control samples showed that keeping the urine samples at 37°C or 
changing the pH to 5.0 had no effect on the total nicotine metabolite concentration 
(figure 2.16). The average nicotine metabolite concentration increase for the urine 
samples taken from smokers and treated with p-glucuronidase was 36.7 percent, 
compared to urine samples taken from non-smokers, which on average had an increase 
of 90.3 percent. The increase in the total nicotine metabolite concentration in the urine 
taken from non-smokers is unlikely to be solely due to the glucuronides, especially as 
the glucuronides of nicotine, cotinine and trans-3 '-hydroxycotinine constitute on 
average 29 percent of the urinary metabolites (Byrd et al 1992). Therefore as the expected 
concentrations for the treated non-smoker urine samples should be less than observed, 
then the increase must be due to another unknown factor interfering with the reaction. 
Due to the time available, no further investigations were carried out to determine why a 
large increase in the concentration of nicotine metabolites was observed in non-smoker 
urine samples after treatment with P-glucuronidase.
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Chapter 3
Urine test for the assessment of smoking status
3.1 Introduction
Smoking is the major preventable cause of mortality and morbidity throughout the 
western world, and recent evidence has suggested that about half of all regular smokers 
will die from their smoking habit (Doll et al 1994). For many years questionnaires were 
used to derive information regarding an individual’s smoking habit (Cope et al 1996 and 
Kharrazi et al 1999). However, often the information an individual gave about their 
tobacco consumption (i.e. if a particular individual classes themselves as a smoker or a 
non-smoker) was found to be incorrect compared to laboratory results. The 
inconsistency in the information obtained may be largely due to the attitude which 
society has towards smokers, (for example a greater understanding of the risks 
associated with smoking and passive smoking) and consequently smokers are likely to 
underestimate their consumption of tobacco or even deny their smoking addiction (Cope 
et al 1996).
Questionnaires which ask about the frequency and the number of cigarettes smoked or 
details of smoking habits (i.e. they presume that everyone is a smoker), rather than 
asking yes/no questions about whether an individual is a smoker or not, were found to 
be more honestly answered (Kharrazi et al 1999). Questions that require a yes/no answer 
may not be as honestly answered because it may be confusing to some individuals 
whether to class themselves as a smoker or not, especially if their smoking habits have 
changed recently or if they have an irregular smoking habit and therefore prefer to class 
themselves as a “social smoker”. A change in smoking behaviour can occur for a variety 
of reasons, although it has been documented that smoking behaviour can alter during 
pregnancy (Fingerhut et al 1990 and Dempsey et al 1998), with some women cutting down on 
the number of cigarettes smoked or even quitting altogether during pregnancy (Kharrazi et
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al 1999). It is important, therefore, to be able to monitor an individual attending a 
particular health clinic, such as a smoking cessation clinic or an antenatal clinic, using a 
simple, reliable method to differentiate smokers from non-smokers which can also be 
used to assess an individual’s daily intake of tobacco related compounds.
Using the Konig reaction Smith et al (1998) reported a clinical sensitivity of 100 
percent and specificity of 97 percent compared to self-reported smoking status, and a 
clinical sensitivity of 95 percent and specificity of 97 percent, compared to a 
radioimmunoassay (RIA) method (Knight et al 1985), which they used as a gold standard. 
Clinical sensitivity refers, in this case, to the proportion of individuals who are 
confirmed to be smokers by RIA (the “gold standard” test) and are also confirmed to be 
smokers by another particular test (the Konig reaction).
To distinguish a non-smoker from a smoker can be extremely difficult. This may be as 
result of an irregular smoking habit (“social smoker”), or the individual not actively 
smoking but being exposed to high levels of ETS through family or work environments. 
Therefore it is difficult to correctly identify “social smokers” and those individuals 
exposed to high levels of ETS using a laboratory test. Thus these individuals may be 
classified as either non-smokers or smokers, depending on when they last smoked or 
were exposed to ETS.
The cut off point for a laboratory test in order to distinguish a smoker from a non- 
smoker can vary depending upon the requirements for which the test is being made. 
Consequently, the cut off point for a laboratory test required by an antenatal clinic may 
be different to the cut off point required by an insurance company. The cut off point for 
an antenatal clinic may be set at a lower point, which would increase the clinical 
sensitivity rate but decrease the specificity rate. This would mean that all smokers 
would be detected with a few non-smokers being misclassified, but the benefits of 
providing pregnant women with all the facts about the effects of smoking and the risks 
to their unborn child, outweighs the misclassification of a few non-smokers. However, 
for an insurance company it may be more suitable to have a higher cut off point
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compared to the antenatal clinic. This would mean a reduction in clinical sensitivity but 
an increase in specificity, which would ensure that all non-smokers would be classified 
correctly but a few smokers would be misclassified. Insurance companies would not 
want to misclassify any non-smokers for legal reasons, as misclassified non-smokers 
might choose to sue if they were not offered discounted insurance premiums due to a 
mistake in a laboratory test distinguishing a smoker from a non-smoker.
The aim of the work in this chapter was to investigate the differences in clinical 
sensitivity and specificity for both qualitative and quantitative measurements using the 
condensing reagents, DETB and DBTB. The condensing reagents DETB and DBTB 
were chosen because they form pink-red chromophores, rather than DMDD or MPED 
which form orange chromophores. When using DMDD or MPED for qualitative results, 
it may be difficult to distinguish a urine sample pre-derivatization from a urine sample 
post-derivatization because of the background colour. However, all four condensing 
reagents could be used for quantitative analyses, providing appropriate blanks were 
prepared.
3.2 Subjects
During a previous study, urine samples were collected from 251 patients attending the 
diabetic clinic at Ealing Hospital (Smith et al 1998). A specific cotinine radioimmunoassay 
method (Knight et al 1985), indicated that this population consisted of 130 non-smokers 
and 120 smokers with 1 borderline result. The current study utilised aliquots of 224 
urine samples (106 RIA determined smokers and 118 RIA determined non-smokers) 
remaining from this study.
The urine samples were subjected to both qualitative and quantitative measurements. 
Quantitative measurements were made before (aqueous results) and after extraction with 
ethyl acetate (organic results), although measurements made using the organic layer 
were carried out on only 95 of the samples from RIA determined smokers and 115
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samples from RIA determined non-smokers. All samples were collected in accordance 
with the ethical code at Ealing Hospital. All samples were also deep-frozen until 
analysis and all analyses were carried out “blind” without reference to self reported 
smoking status or the results of the RIA.
3.3 Methods
3.3.1 Cotinine radioimmunoassay
For the purpose of this study, an RIA method described by Knight et al (1985) was used 
as the gold standard. A gold standard is a well-documented method that can reliably 
distinguish between two categories, for example an individual that is exposed to high 
levels of nicotine (i.e. a smoker) and an individual who is exposed to low levels of 
nicotine (i.e. a non-smoker). Aliquots (lOpL) of the urine samples or cotinine 
calibrators (0.14 -  4.26pmol/L) were incubated overnight with cotinine antibody and 
125I cotinine. Bound and free fractions were separated using a polyethylene glycol 
assisted second antibody technique. The radioactivity in the bound fraction was 
counted and cotinine concentrations were estimated using a 4-parameter logistic curve- 
fitting program. Within and between batch imprecision were 5.1 percent and 7 percent 
respectively. The cut off point was determine to be 1.14 pmol/L, which was determined 
by a simple histogram.
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3.3.2 The Konig reaction
The total nicotine metabolite concentration was determined both qualitatively and 
quantitatively. This involved adding 1 mL of individual nicotine metabolite, urine, or 
cotinine solution to sodium acetate buffer (400 pL, 4 M, pH 4.7), followed by 
potassium cyanide (200 juL, 10% w/v) and chloramine-T (200 pL, 10% w/v). The 
solution was mixed well before the addition of the condensing reagent ( 1 mL, 1% w/v, 
DETB water: acetone 50:50 or DBTB in acetone). The reaction mixture was again 
mixed well and allowed to stand for 20 minutes. Absorbance measurements were made 
both before and after extraction with ethyl acetate (1 mL).
Qualitative assessment was made by simple observation of the pink colour in the ethyl 
acetate layer. Absorbance measurements of the aqueous and organic layers were made 
at 525 nm and 533 nm, respectively. A stock solution of cotinine (5 pg/mL) was used 
to determine the equivalent nicotine metabolite concentration. In addition a sample 
blank was used from both self reported smokers and non-smokers, and was analysed 
following the basic method, except chloramine-T was omitted.
3.3.3 Statistical analysis
The optimum cut off point for each of the condensing reagents was determined by a 
Receiver Operating Characteristics (ROC) curve. An ROC curve is a simple graph that 
depicts the pairs of true positive rates and false positive rates that correspond to each 
possible cut off point for a particular diagnostic test result (Sackett et al 1991). The cut off 
point is then determined by plotting 1-specificity (false positive rate) against sensitivity 
(true positive rate).
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TEST Positive 
Negative
GOLD STANDARD
Positive Negative
TP FP
FN TN
SENSITIVITY = TP TP = True Positive
TP + FN FN = False negative
SPECIFICITY = IN  TN = True Negative
TN + FP FP = False Positive
An overall test efficiency may also be calculated as:
EFFICIENCY = True negative + true positive 
Total patients tested
Efficiency is the proportion of patients correctly categorised by the test, in this instance 
the number of patients correctly categorised as smokers or non-smokers using the Konig 
reaction either quantitatively or qualitatively (Jones and Payne 1997).
Correlation studies amongst the RIA determined smokers, were carried out using a 
Spearman Rank analysis.
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3.4 Results
The urinary cotinine concentrations determined by cotinine RIA ranged from 0.06 
pmol/L to 0.97 fimol/L with a median of 0.1 pmol/L for the non-smokers, compared to 
the urine samples taken from smokers, which ranged from 1.48 pmol/L to 76.5 pmol/L 
with a median of 19.3 pmol/L (Table 3.1).
The urinary cotinine equivalent concentrations determined using DETB (aqueous 
results) ranged from <0.1 pmol/L to 12.9 pmol/L with a median of 1.25 pmol/L for the 
non-smokers and 4.3 pmol/L to 282 pmol/L, with a median of 45 fimol/L for the 
smokers. DBTB (aqueous results) cotinine equivalent concentrations ranged from <0.1 
pmol/L to 9.8 fimol/L, with a median of 4.29 pmol/L for the non-smoker, compared to
5.2 pmol/L to 324 pmol/L with a median of 30.3 pmol/L for the smokers (Table 3.1). 
Urinary cotinine equivalent results for DBTB (organic results) ranged from <0.1pmol/L 
to 12.6 pmol/L with a median of 0.91 pmol/L for the non-smokers, and 2.6 pmol/L to 
212 fj,mol/L with a median of 23.8 pmol/L for the smoker (Table 3.1).
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NON-SMOKERS SMOKERS
Median
(p,mol/L)
Range
(|imol/L)
Median
(fj.mol/L)
Range
(fimol/L)
RIA 0.1 0.06-0.97 19.3 1.48-76.5
DETB
(aqueous results)
1.25 <0.1-12.9 45 4 .3 -2 8 2
DBTB
(aqueous results)
4.29 < 0.1-9 .8 30.3 5 .2 -3 2 4
DBTB
(organic results)
0.91 <0.1-12.6 23.8 2.6-212
Table 3.1 A summary of the cotinine equivalent concentrations
The cut off point for the quantitative results were determined by an ROC curve and are 
summarised in table 3.2. The cut off point for DETB (aqueous results) was determined 
to be 6 pmol/L, giving a clinical sensitivity of 98 percent and specificity of 97 percent 
(figures 3.1 and 3.2). The cut off point for DBTB (aqueous results) was determined to 
be 8.5 jimol/L, giving a clinical sensitivity and specificity of 95 percent (figure 3.3 and 
3.4), compared to the cut off point for DBTB (organic results) of 4 pmol/L which had a 
clinical sensitivity and specificity of 96 percent (figure 3.5 and 3.6).
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SENSITIVITY SPECIFICITY
Qualitative (organic results)
DETB 94% 100%
DBTB 100% 99%
Quantitative (aqueous results)
DETB 98% 97%
DBTB 95% 95%
Quantitative (organic results)
DBTB 96% 96%
Table 3.2 A summary of the clinical sensitivity and specificity obtained for qualitative 
and quantitative results
Qualitative measurements using DETB (organic results), gave a clinical sensitivity of 
94 percent and specificity of 100 percent compared to DBTB (organic results) which 
had a clinical sensitivity of 100 percent and specificity of 99 percent. There was an 
overall improvement in efficiency from 97 percent using DETB as the condensing 
reagent to 99.5 percent using DBTB.
Correlation studies amongst the RIA determined smokers, were carried out using a 
Spearman Rank analysis. The findings were as follows: RIA vs DETB (aqueous 
results) rs = 0.890; n =106; p<0.01 (Figure 3.7), RIA vs DBTB (aqueous results) rs = 
0.790; n =106; p<0.01 (Figure 3.8); RIA vs DBTB (organic results) rs = 0.84; n = 95; 
p<0.01 (figure 3.9) and DETB (aqueous results) vs DBTB (aqueous results) rs = 0.871; 
n =  106; p<0.01 (Figure 3.10).
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Figure 3.7 A correlation study between RIA determined smokers and DETB aqueous 
results
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Figure 3.8 A correlation study between cotinine RIA determined smokers and DBTB 
aqueous results
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Figure 3.9 A correlation study between cotinine RIA determined smokers and DBTB 
organic results
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3.5 Discussion
The modified Konig reaction is a simple test that can be used to determine an 
individual’s smoking status. When used qualitatively, DBTB appeared to be the more 
efficient condensing reagent with a clinical sensitivity of 100 percent and specificity of 
99 percent, compared to DETB, which had a clinical sensitivity of 94 percent and 
specificity of 100 percent. The overall efficiency was determined to be 97 percent using 
DETB, which increased to 99.5 percent using DBTB. The difference in the clinical 
sensitivity and specificity between DETB and DBTB could be due to the improvement 
in partitioning between the aqueous layer and organic layer. Therefore DBTB has the 
advantage of being able to distinguish between borderline urine samples (i.e. smoker or 
non-smoker) which were misclassified by DETB.
Quantitative results suggested that the optimum clinical sensitivity and specificity was 
achieved using DETB as the condensing reagent (clinical sensitivity of 98 percent and 
specificity of 97 percent), which implies that, when used quantitatively, measurements 
obtained using DETB were equal to those with DBTB. The clinical sensitivity and 
specificity for DBTB results (aqueous results and organic results) were only 3 percent 
and 2 percent respectively less than DETB results. However, the number of urine 
samples obtained with a urinary cotinine equivalent concentration around the cut off 
point was very few and the difference in sensitivity and specificity may be due to one or 
two samples being misclassified as a smoker or non-smoker, especially as the 
distinction between a smoker and non-smoker is notoriously difficult to make, since no 
individual can be said to be totally unexposed to tobacco smoke. Since the numbers 
around the cut-off point are small, it is likely that these results are not significant.
The correlation studies for the results of the Konig reaction compared to the results 
obtained by the “gold standard” (RIA) all gave an rs > 0.790. This confirms that the 
Konig reaction and the RIA method are producing similar results, although overall the 
Konig reaction produced higher cotinine equivalent values, compared to the RIA 
method, but this is as expected as the RIA method only measures cotinine and the
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Konig reaction measures the total nicotine metabolite concentration. The correlation 
studies also showed that there are one or two samples that appear to have a 
significantly higher cotinine equivalent concentration compared to the cotinine 
concentration determined by the RIA method. These results may imply that these 
individuals have a different nicotine metabolic profile and that certain metabolites 
present in their urine are being measured by the Konig reaction but not by RIA. One 
possibility is that these individuals are either unable to metabolise nicotine or 
metabolise nicotine poorly using phase one metabolism due to a genetic variability of 
the cytochrome P450 enzyme, CYP2A6. Individuals who carry the null or inactive 
alleles (CYP2A6*2 and CYP2A6*3) for this enzyme, have an impaired nicotine 
metabolism and are significantly protected against becoming a tobacco dependent 
smoker (Pianezza et al 1998). Recent work has also suggested that nicotine is metabolised 
differently in the pregnant and the non-pregnant (Dempsey et al 1998) and that there are 
also inter-racial differences in nicotine metabolism (Benowitz et al 1999).
The one or two samples that appear to have a significantly higher cotinine equivalent 
concentration determined by the Konig reaction compared to the cotinine concentration 
determined by RIA may be due to these individuals having an altered metabolic profile 
and thus a greater concentration of certain nicotine metabolites may be detected; these 
may include nicotine-lW-oxide, 3 '-hydroxy cotinine and 3 '-hydroxy cotinine 
glucuronide. These individuals may also have an increase in the concentration of 
cotinine and nicotine glucuronide, but the Konig reaction is unlikely to be able measure 
these particular metabolites directly, due to carbohydrate residue being attached to the 
nitrogen atom on the pyridine ring (figure 2.2). Therefore to determine the 
concentration of these metabolites the urine has to be pre-treated with the enzyme P- 
glucuronidase, which is able to cleave the nicotine-derived portion from the 
carbohydrate residue, thus allowing the nicotine-derived portion to be measured in the 
usual way. The increase in the cotinine equivalent concentration between the untreated 
and treated urine samples is proportional to the amount of cotinine and nicotine 
glucuronide present in the urine sample.
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Chapter 4
Structural determination of the derivatives of nicotine 
and cotinine produced from the Konig reaction
4.1 Introduction
The Konig reaction is known to enable nicotine metabolites to react with a condensing 
reagent, such as DETB, to form coloured chromophores. The chemistry involved in this 
reaction and the final derivatized structures are not known for certain, although 
suggestions have been made (O’Doherty et al 1990 and Rustemeier et al 1993) (figure 4.1). 
O’Doherty et al (1990) put forward a structure for nicotine and its metabolites 
derivatized with either DETB or DMDD. However, there appeared to be no evidence 
given as to why they had suggested these structures. Rustemeier et al (1993) isolated 
nicotine derivatized with DETB and subjected the isolated compound to various 
analytical procedures, before they decided on a final structure. The analytical 
procedures they used included mass spectrometry (MS), infrared spectroscopy (IR) and 
nuclear magnetic resonance spectroscopy (NMR).
101
o
R .Et
O
Et.
NA.
IEt
s -  N 0  IEt
S
OH
CN
R = N ICH3
a = Nicotine
R =
c h 3
b = Cotinine
Figure 4.1: Molecular structures of DETB derived nicotine metabolites as proposed by 
O’Doherty et al (1990) (1) and Rustemeier et al (1993) (2).
The main aim of the work in this chapter was to confirm, or otherwise, the structure of 
the derivative formed from nicotine and DETB, using the method described by 
Rustemeier et al (1993). The analysis would be carried out using mass spectrometry, IR 
and NMR. Mass spectrometry was then to be used to extend this work by determining 
the relative molecular mass (RMM) of the derivatives formed from nicotine and 
cotinine using the other condensing reagents.
HPLC was to be used as an analytical procedure to ensure the retention time for the 
nicotine derivative obtained using the “preparative” conditions described in 4.2.1, was 
the same as that for nicotine derivatized using the “analytical” conditions described in 
4.2.2.
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4.2 Materials and methods
The mass spectrometer used was a VG quattro with a Harvard apparatus pump II for 
direct injection. Infrared spectroscopy was carried out with an ATI Mattson Genesis 
FTIR. NMR spectra were obtained in CDCI3 solution using a Bruker AC 250. The 
HPLC system consisted of a Milton Roy CM 4000 multiple solvent delivery system 
pump, an LKB Biochrom ultraspec II spectrophotometer and a Kipp and Zonen BD9 
two channel chart recorder. A 100 pL loop and a Ci8 column were also used and the 
flow rate was always set to 1 mL/min. Solutions were centrifuged using a Sorvall TC 6 
bench top centrifuge. Absorbance measurements were obtained using a Cecil 9500 
Super Aquarius. Solid phase extraction was carried out using a Bond Elute Cs column.
4.2.1 Isolation of nicotine derivative
The structure of the derivative of nicotine derivatized with DETB was determined using 
a modification of the method described by Rustemeier et al (1993). A mixture of 
nicotine (40 mL, 0.01 M), sodium acetate buffer (16 mL, 4 M, pH 4.7), potassium 
cyanide (8 mL, 0.8 g, 1.5 M), chloramine-T (8 mL, 0.8 g, 0.8 M) and DETB (20 mL, 
0.4 g, 0.1 M, water: acetone, 50:50 v/v) was allowed to react overnight in the dark. The 
solution was centrifuged for 10 minutes at approximately 3,000 rpm and the supernatant 
removed. The precipitate was washed with water and resuspended in distilled ethyl 
acetate (10 mL). The solution was dried with magnesium sulphate and the solvent 
removed under reduced pressure. The compound was further purified using a silica 
column (20 cm x 4 cm) and a gradient mobile phase, ethyl acetate (100 mL), ethyl 
acetate: 2 % methanol (200 mL), followed by ethyl acetate: 4 % methanol (500 mL). 
The pink fractions (nicotine derivative) were collected and checked by TLC (ethyl 
acetate: 4 % methanol, Rf 0.11) and the appropriate fractions pooled together. The 
solvent was removed under reduced pressure, resulting in a dark red solid (7.8 mg). 
The isolated fraction (purified nicotine derivative) was further analysed using IR, NMR, 
mass spectrometry and HPLC.
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4.2.2 Analysis by HPLC
HPLC was used to compare the retention time for the isolated DETB nicotine derivative 
to that of the nicotine derivatized using the "analytical” conditions described below. A 
small amount of the isolated nicotine derivative was dissolved in methanol to form a 
concentrated pink solution. The solution was then subjected to chromatography with 
UV detection at 530 nm using a mobile phase of acetonitrile: heptane sulphonic acid 
(0.005 M) 45:55. This mobile phase was a modification of mobile phases described by 
Moore et al (1990) and Ubbink et al (1993).
A 10 pg/mL solution of nicotine (1 mL) was added to sodium acetate buffer (400 pL, 4 
M pH 4.7), potassium cyanide (200 pL, 1 % w/v) and chloramine-T (200 pL, 1 % w/v). 
The solution was mixed well before the addition of the condensing reagent, DETB (1 
mL, 1 % w/v 50:50 acetone: water). After 20 minutes the solution was placed on a solid 
phase extraction (SPE) column, pre conditioned using methanol (2 mL) followed by 
distilled water (2 mL). The column was washed with distilled water (2 mL) which was 
used to remove any unreacted potassium cyanide and chloramine-T leaving the nicotine 
derivative attached to the column. The nicotine derivative was then eluted from the 
column with methanol (1 mL) and analysed by HPLC using the same conditions as 
described above.
4.2.3 Analysis by mass spectroscopy
A small amount of the isolated nicotine derivative was resuspended in methanol (2 mL) 
to form a dark pink solution and was directly injected in to the mass spectrometer set to 
detect negative ions. Further studies were carried out using the “analytical” conditions 
as described in 4.2.2 using nicotine or cotinine (50 pg/mL) derivatized with the other 
condensing reagents, although DBTB and MPED will only dissolve in 100 percent 
acetone. After twenty minutes, distilled water (2 mL) was added to each sample before 
the solution was transferred to an SPE column, which had been pre-conditioned with
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methanol (2 mL), followed by distilled water (2 mL). It was observed that the addition 
of water to the sample pre SPE enabled a greater amount of the derivative to remain on 
the SPE column during the wash stage. The column was then washed with distilled 
water (2 mL) and the derivative eluted from the column with methanol (2 mL). Each 
sample was then stored until analysis in a container wrapped in aluminium foil, as the 
product is light sensitive. This was observed when a sample was left on the bench in 
direct sunlight for one hour, after which time the colour of the solution had begun to 
fade.
4.3 Results and discussion
4.3.1 Structural determination of the nicotine DETB derivative
The purified nicotine derivative was subjected to various analytical procedures to 
confirm if either structure la  or 2a were correct.
The results from the infrared spectroscopy (figure 4.2) showed that there was a strong 
peak at 2176 cm'1. In this part of the infrared spectrum, very few bonds absorb with the 
exception of CN triple bonds. Therefore, the peak at 2176 cm*1 suggests that the 
isolated nicotine derivative contains a CN triple bond. The structure 2a, suggested by 
Rustemeier et al (1993) contains a CN triple bond, whereas in structure la  no such 
bonds are present.
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Figure 4.2 Infrared spectrum for isolated nicotine derivative.
Based on the chemical reactions involved in the derivatization of nicotine and its 
metabolites, using the Konig reaction (figure 2.1), Rustemeier et al (1993) positioning 
of the R group may not be the only structure able to form from this reaction. Their 
suggestion of structure 2 (figure 4.3) would result if the OH group from water attached 
to the 6-position of the nicotine metabolite. The alternative structure 8 would result if 
the OH group were attached to the 2-position of the nicotine metabolite.
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Figure 4.3 Molecular structures of DETB derived nicotine metabolites as proposed by 
Rustemeier et al (1993) (2) and an alternative structure (8).
However, it would be extremely difficult to differentiate between these two products 
using mass spectrometry, IR or NMR. An attempt was made to grow crystals for x-ray 
analysis, since this technique would have given a definite answer. A small amount of 
the isolated nicotine derivative was dissolved in ethyl acetate and various mixtures of 
ethyl acetate and petrol and the solvent allowed to slowly evaporate off, but no suitable 
crystals were formed, only amorphous powders.
The NMR spectrum of the isolated nicotine derivative is shown in figure 4.4. The 
relative integration (1:1) of the N-CH2 peaks of the N-ethyl group(s) at 4.6 5 to that for 
the alkene protons in the 7.3 - 8.2 8 region indicate that there is only one DETB unit in 
the compound, as in structure 2a, whereas structure la  would require two such units. 
This further confirms that the structure suggested by O’Doherty et al (1990) was not 
correct. The NMR results published by Rustemeier et al (1993) are very vague and no 
NMR spectrum was given to compare with the results obtained in this study. However, 
they did comment on the difference between the spectrum of nicotine and their reaction
NICOTINE DERIVATIVE. CODE 3230 in CDC13 for 1H— KERRY
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Figure 4.4 NMR spectrum of the isolated nicotine derivative
product. They suggested that the changes for the protons of the double bond region (8 
between 7.2 and 8.2), where the coupling constants increased to ca.17 Hz, could be 
explained by the opening of the pyridine ring leading to an alkene with a trans 
configuration as in structure 2. Of course the same would be true for structure 8.
The results for the HPLC suggest that nicotine derivatized using the “analytical” 
conditions had the same retention time as the isolated nicotine derivative (9.0 minutes). 
The HPLC traces for the “analytical” conditions (i.e. the total reaction mixture after 
SPE) appeared to have one peak up to a retention time of 15 minutes. If any other 
compounds (for example structure la ) were present with a retention time greater than 
15 minutes, then they would have been detected in later runs. No such peaks were seen 
so it can be assumed that no other compounds were present.
4.3.2 Structural determination of derivatives of nicotine and cotinine by mass 
spectrometry
Mass spectrometry was used by Rustemeier et al (1993) to confirm the RMM of the 
isolated DETB nicotine derivative. In this current study the predicted and observed 
molecular ions for either nicotine or cotinine derivatized with the various condensing 
reagents are shown in table 4.1. The reason for the observed peak being M -l was a 
result of the mass spectrometer set to negative ion mode. This results in the observed 
ions having a RMM of one less than that expected.
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NICOTINE
METABOLITE
CONDENSING
REAGENT
PREDICTED RMM 
FOR 
RUSTEMEIER’S 
STRUCTURE
PREDICTED 
RMM FOR 
O’DOHERTY’S 
STRUCTURE
OBSERVED
PEAK
(M-l)
Nicotine DETB 387 543 386
Cotinine DETB 401 557 400
Nicotine DBTB 443 599 442
Cotinine DBTB 457 613 456
Nicotine DMDD 331 487 330
Cotinine DMDD 345 501 345
Nicotine MPED 421 577 420
Cotinine MPED 435 591 434
Table 4.1 Predicted and observed molecular ions for the derivatives of nicotine and 
cotinine.
Molecular ions for the derivatives of nicotine and cotinine were determined by 
observing a range of masses from 50 to 750. The results indicate that structures 2a and 
2b (figures 4.5- 4.6) (or presumably 8a or 8b) were present but no ions were present to 
confirm either structure la  or lb.
Overall, the results from the infrared spectroscopy, NMR and mass spectrometry found 
no evidence for structure 1. This is supported by a CN triple bond present on the infra 
red spectrum, only one DETB unit present on the NMR spectrum and correctly 
identified molecular ions by mass spectrometry. Therefore, these results confirm that 
the isolated DETB nicotine derivative was the same as structure 2 or 8. However, the 
yield for the isolated nicotine derivative was only 5 percent so it may be possible that a 
compound with the structure 1 was formed, but was not isolated using the “preparative” 
conditions described in 4.2.1.
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Figure 4.5 Predicted final structures of nicotine or cotinine derivatized 
using DETB or DBTB
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Figure 4.6 Predicted final structures 
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4.4 Solvatochromism
During the “preparative” reactions (4.2.1), it was observed that the maximum 
absorbance wavelength for the isolated nicotine derivative altered depending on the 
solvent used (e.g. water or ethyl acetate). A possible reason for this change is that the 
derivative is able to exhibit solvatochromism. Solvatochromism refers to a compound 
whose absorbance maximum wavelength will depend on the polarity of its 
surroundings.
The pyridinium iV-phenoxide betaine dye 9 (figure 4.7a) is a compound showing 
negative solvatochromism. This dye is known to exhibit one of the largest 
solvatochromic shifts ever observed (Reichardt 1992). The absorption bandwidth is 
shifted by 375 nm from a maximum wavelength of 453 nm when in water to 810 nm in 
diphenyl ether. When 9 is placed in a polar solvent like methanol the highly dipolar 
ground state is more stable compared to the less dipolar excited state and this results in 
a greater amount of energy being required to excite an electron from the ground state to 
excited state, which is observed as a lower wavelength (515 nm) absorption. However, 
when 9 is placed in a non-polar solvent, such as ethyl acetate, the ground state is made 
less stable and the excited state more stable and therefore the energy required to excite 
an electron is less, which results in the maximum wavelength shifting to a longer 
wavelength (769 nm) (figure 4.7b).
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Figure 4.7 a Molecular structure of pyridinium iV-phenoxide betaine dye 9
b Diagrammatic representation of the energy states of 9 in different solvents
The “preparative” conditions described in 4.2.1 were slightly modified to determine if 
nicotine derivatized with the other condensing reagents formed solvatochromic 
compounds. A mixture of nicotine (20 mL, 0.01 M), sodium acetate buffer (8 mL, 4M, 
pH 4.7), potassium cyanide (4 mL, 0.4 g, 1.5M), chloramine-T (4 mL, 0.4g, 0.8 M) and 
a condensing reagent (10 mL, 0.4 g, DETB and DMDD water: acetone, 50:50 v/v, 
DBTB and MPED 100 % acetone) was allowed to react overnight. The solution was 
centrifuged for 10 minutes at approximately 3,000 rpm and the supernatant removed. A 
small amount of the precipitate was then dissolved in various solvents (water, ethyl 
acetate: methanol and ethyl acetate) and the maximum wavelength determined by 
scanning between 250-900 nm.
The results for the wavelengths obtained for all the derivatives in various solvents are 
shown in table 4.2. The results suggest that, when nicotine is derivatized with any of 
the condensing reagents the derivative formed is able to exhibit negative 
solvatochromism, that is the maximum wavelength shifts to a longer wavelength as the 
surrounding solvent changes from a polar (water) to a less polar (ethyl acetate) solvent.
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CONDENSING
REAGENT
MAXIMUM 
WAVELENGTH IN 
WATER
MAXIMUM 
WAVELENGTH IN A 
MIXTURE OF ETHYL 
ACETATE: 
METHANOL (1:1)
MAXIMUM 
WAVELENGTH 
IN ETHYL 
ACETATE
DETB 531 549 610
DBTB 518 557 564
DMDD 505 509 518
MPED 497 550 580
Purified DETB 
nicotine
538 
(in methanol)
564 550
Table 4.2 Maximum wavelengths obtained when using different solvents.
Generally the results follow the expected pattern: when the derivatives were placed in 
water the absorbance at the shorter wavelength was observed, in ethyl acetate the 
absorbance at a longer wavelength was observed and when the derivatives were placed 
in a mixture of ethyl acetate and methanol the absorption was in between the previous 
two wavelengths. However, for the purified DETB nicotine derivative the observed 
wavelengths did not follow this expected pattern. When the purified nicotine derivative 
was placed in methanol the maximum wavelength observed was slightly higher than 
that of the DETB derivative, which is what would have been expected as methanol is 
less polar than water. When the purified nicotine derivative was placed in a mixture of 
ethyl acetate and methanol the absorbance shifted from 538nm to 564nm as expected. 
However, on comparing the wavelengths with the other DETB derivative the 
wavelengths were similar but the purified nicotine derivative wavelength was slightly 
longer, 564 nm compared to 549 nm. This can be explained as the ratio of ethyl acetate 
and methanol were not measured exactly, so if the purified nicotine derivative was 
added to a mixture containing slightly more ethyl acetate than the mixture used for the 
DETB derivative then the observed wavelength for the purified nicotine derivative 
would be expected to be longer. The reason for the wavelength for the purified nicotine 
derivative when placed in ethyl acetate not being the same as that observed for the 
DETB derivative is unknown. It is possible that the solvatochromic effects for the
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“analytical” samples are a result of additive effects from a number of compounds in the 
mixture. It may also be that this is an odd result due to contamination of the derivative 
or solvent. Ideally, this part of the experiment should have been repeated but time did 
not allow for this to be done.
Overall the results suggest that the derivatives of nicotine do exhibit negative 
solvatochromism, although when comparing the absorption shifts to 9 the absorption 
shifts for the derivatives are very small, and therefore it would be highly unlikely that 
they could be used as solvatochromic compounds. However, from this observation, it is 
important when reporting the maximum wavelength for all these derivatives and 
possibly derivatives of other nicotine metabolites, that the solvent system used to 
determine a spectrum is also reported.
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Chapter 5
The effect of surfactants on the Konig reaction
5.1 Introduction
The Konig reaction is a simple analytical technique that can be used to measure nicotine 
and its metabolites in a urine sample, and in recent years this reaction has been 
incorporated into two different near patient tests to determine an individual’s smoking 
status (Cope et al 1996 and Eswara et al 1996). Cope et al (1996) published a simple near 
patient urine test they referred to as the Smoking Test Device, although it is now 
referred to as SmokeScreen (http://www.bham.ac.uk) to distinguish smokers from non- 
smokers. This device consists of two parts; an adapted fixed-volume 2 mL syringe and 
cap, and a barrel and lower reaction chamber with a membrane seal. All the dried 
reagents (potassium cyanide, DETB, citric acid and sodium citrate) are contained in the 
reaction chamber, except chloramine-T, which is isolated for stability reasons in a 
washer-like annulus, with a space between two tightly fitting plastic discs, which forms 
a seal on top of the reaction chamber (figure 5.1).
The fixed-volume syringe can then be used to measure 2 mL of unprepared urine, which 
is transferred into the barrel, forming a permanent seal between the cap and the barrel. 
As the syringe passes through the barrel, the tip breaks the seal, causing the chloramine- 
T to be dispensed into the reaction chamber below. The urine is then injected onto the 
reagents, which dissolve, starting the reaction. As the device contains DETB as the 
condensing reagent, pink chromophores will form in a concentration dependent manner, 
if nicotine and its metabolites are present. After 20 minutes, the colour change of the 
urine sample can be observed to give either a qualitative or semi-quantitative 
assessment of an individual’s smoking status or measured in a simple 
spectrophotometer to give the concentration of nicotine and its metabolites with 
reference to a cotinine standard.
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Figure 5.1 (a) SmokeScreen device before use, comparing a sampling syringe, and 
reaction chamber, containing dry reagents: (b) an enlargement of the seal, with the 
chloramines-T isolated between the two plastic discs: (c) the assembled device after 
addition of the sample (Cope et al 1996)
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Cope et al (1996) reported that qualitatively the SmokeScreen produced a sensitivity 
and specificity of 89 percent and 100 percent, respectively and a sensitivity and 
specificity of 89.9 percent and 98.9 percent, respectively for quantitative results. The 
device was also reported to have a lower limit of detection of 0.6 pg/mL (3.4 pmol/L) 
and the cut off point to differentiate between smokers and non-smokers was 
predetermined to be 10 pg/mL.
Cope et al (2000) published another paper describing a modification to the 
SmokeScreen to enable exposure to environmental tobacco smoke to be quantified. 
This device is referred to as the Passive SmokeScreen, which is the same as the 
SmokeScreen, except that it measures saliva and the condensing reagent has been 
changed from DETB to DMDD. The results given were very vague and no explanation 
was given as to why they had changed the condensing reagent to DMDD. One possible 
reason why DMDD was chosen is that it enables the sensitivity of the Passive 
SmokeScreen to increase, thus allowing smaller quantities of nicotine metabolites to be 
detected. This is in agreement with the findings in chapter 2, which suggested that 
DMDD produced the highest absorbance values, when comparing the results with the 
other three condensing reagents used.
The SmokeScreen device has been used in clinical trials to improve information 
feedback to pregnant women and the Passive SmokeScreen has been used in pilot 
studies to measure passive smoking in bar staff and children with asthma. However, the 
disadvantage of both the SmokeScreen and Passive SmokeScreen is that they involve 
the use of potassium cyanide.
Eswara et al (1996) reported that they had developed a simple strip test referred to as the 
NicCheck. The advantage of the NicCheck over both the SmokeScreen and Passive 
SmokeScreen is that it uses the less toxic compound potassium thiocyanate instead of 
potassium cyanide. The NicCheck strip consists of a paper strip consisting of four 
regions, with each region containing a different reagent (acetate buffer, potassium 
thiocyanate, chloramine-T and DETB). The test strip is placed in a urine sample and as
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the urine diffuses up the test strip the reagents dissolve and then react together. After 30 
minutes the colour of the test strip and urine sample remaining in the container are 
observed, and a positive result is confirmed by the test strip turning pink. (The 
sensitivity and specificity of the NicCheck was reported to be 98.7 percent and 99.4 
percent respectively.) However, from the results obtained in this current study (5.3), it 
was observed that the absorbance obtained when using potassium thiocyanate was 
reduced by up to 90 percent compared to that when using potassium cyanide. 
Therefore, it was concluded that potassium thiocyanate could only be realistically used 
to distinguish heavy smokers from non-smokers and it would be extremely difficult, if 
not impossible, to differentiate light smokers from non-smokers. No other publications 
have been found relating to this test, suggesting that it has not found wide usage or 
acceptability.
Esteve-Romero et al (1995) reported that they had improved the Konig reaction to 
determine (using aniline as the condensing reagent) the concentration of pyridine, 
pyrrolyl-methylpyridine and nicotinic acid in water with the addition of a surfactant to 
the reaction mixture. This study looked at three different types of surfactant, an anionic 
surfactant, sodium dodecyl sulphate (SDS) (figure 5.2), a cationic surfactant, N- 
cetylpyridinium chloride (NCPC) (figure 5.2), and a non-ionic surfactant, Triton X-100 
(figure 5.2) to determine which type of surfactant, if any, would enhance the overall 
absorbance of the reaction. They concluded that when SDS was added to the reaction 
mixture the absorbance obtained had increased, consequently increasing the molar 
absorptivities.
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Figure 5.2 structures of surfactants
A surfactant describes a species that accumulates at the interface of two fluids and 
modifies the properties of the surface. A typical surfactant molecule is made up of two 
parts, a long hydrophobic hydrocarbon tail that can dissolve in hydrocarbon and other 
non-polar materials and a hydrophilic head that dissolves in a polar solvent. When a 
surfactant is added to a solvent, such as water, the surfactant molecules organise 
themselves so that their hydrophobic tails have as little contact with the water molecules 
as possible. The surfactant molecules are held together by hydrogen bonds and once the 
concentration of the surfactant exceeds the critical micelle concentration (cmc), the 
surfactant molecules spontaneously start to form into micelles (Figure 5.3) (Harris 1999). 
The shapes of micelles can vary with the concentration of surfactant used, although at 
the cmc spherical micelles usually form, whereas at higher concentrations the micelles 
more commonly form flattened spheres and rod-like shapes.
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Figure 5.3 Possible structure of a micelle
Micelles are known to exhibit several properties that can facilitate analytical 
measurements. These include their ability to solubilise and concentrate analyte, alter 
acidity and polarity of solutes and modify reaction rates (Egekeze et al 1997). Micelles are 
also able to solubilise, within their local environment, compounds that are insoluble or 
sparingly soluble in water, due to the interior of the micelle resembling a non-polar 
organic solvent (Egekeze et al 1997). This is important as surfactants can be used instead 
of organic solvents.
Esteve-Romero et al (1995) suggested that since at pH 4.5 aniline is protonated 
(positively charged) it is therefore attracted by ionic interactions to the anionic 
(negatively charged) SDS micelles. They also reported that when NCPC was added to 
the reaction mixture the absorbance increased slowly with the concentration of 
surfactant, but at pH 4.5 both the aniline and the glutaconic aldehyde of nicotinic acid 
will be protonated and therefore should be repelled by the cationic NCPC micelles. 
However, they suggested that this unexpected result might be due to hydrophobic 
interactions, which are independent from the charge of the surfactant, and allow the 
association between the non-ionic glutaconic aldehyde and NCPC micelles to occur.
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Therefore, the association between the glutaconic aldehyde and surfactant will increase 
as the concentration of NCPC increases.
Egekeze et al (1997) reported that they had enhanced the determination of cyanide ions 
in organic sample matrices using the cationic surfactant cetyltrimethylammonium 
bromide (CTAB) (figure 5.4). The determination of cyanide ions involved a 
spectroscopic method they described as the pyridine-barbituric acid method. This 
method is in fact a modification of the Konig reaction, where a known amount of 
pyridine is used to allow determination of the concentration of cyanide ions, (the reverse 
of the work described in chapter 2). The condensing reagent they used was barbituric 
acid and the surfactant CTAB was mixed with sodium hydroxide, to ensure the solution 
was alkaline. In an alkaline solution the glutaconic aldehyde would be deprotonated 
and attracted to the cationic surfactant by ionic interactions.
CH3
CH3(CH2) 14CH2—  N—  CH3 Br"
CH3
Figure 5.4 Structure of cetyltrimethylammonium bromide (CTAB)
Capella-Peiro et al (2001) reported a simple flow injection method based on the Konig 
reaction to detect nicotinic acid in commercial pharmaceuticals. The effects of the four 
surfactants, NCPC, CTAB, Triton X-100 and SDS with various condensing reagents, 
aniline, / 7-toluidine, and /?-sulphanilic acid were studied. The reaction was carried out at 
pH 7.0 and they reported what they described as absorbance enhancement factors for 
aniline,/?-toluidine and/?-sulphanilic acid as 3.3, 5.2 and 4.3 for NCPC, and 2 .6 , 3.4 and
4.1 for CTAB respectively.
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Capella-Peiro et al (2001) concluded that at pH 7.0 nicotinic acid and /?-sulphanilic acid 
are deprotonated and negatively charged, whereas aniline and /?-toluidine are neutral. 
Therefore, there is a strong association between the various condensing reagents and the 
glutaconic aldehyde of nicotinic acid and the cationic NCPC or CTAB micelles by 
electrostatic and/or hydrophobic forces. As SDS is an anionic surfactant, there would 
be a repulsion between the anionic nicotinic acid or /?-sulphanilic acid and the SDS 
micelles, which is probably the reason why a lower absorbance was observed.
The aim of the work in this chapter was to determine if the addition of surfactants, such 
as SDS could be used to enhance the sensitivity of the Konig reaction using potassium 
thiocyanate. If the sensitivity of the Konig reaction could be enhanced, then it might be 
possible to manufacture an improved device to determine an individual’s smoking 
status. This possible device would then have the advantage over both the SmokeScreen 
and Passive SmokeScreen of using a less toxic compound than potassium cyanide, and 
could also have a greater sensitivity compared to the NicCheck. The surfactants that 
were to be used were sodium dodecyl sulfate (SDS), dodecyl benzene sulfonic acid 
(DBS) and Triton X-200 (anionic surfactants), N-cetyl pyridium chloride (NCPC) and 
tetradecyl trimethyl ammonium bromide (TTAB) (cationic surfactants) and Triton X- 
100 (non-ionic surfactant).
5.2 Materials and methods
The surfactants sodium dodecyl sulphate, dodecyl benzene sulfonic acid, Triton X-200, 
N-cetyl pyridium chloride, tetradecyl trimethyl ammonium bromide and Triton X-100 
were purchased from Sigma (Poole, Dorset, UK). Potassium thiocyanate was also 
purchased from Sigma The concentration of the surfactant used was 0.5 M, unless no 
RMM was available for a particular surfactant then 2x105 ppm was used instead. 
Absorbance measurements were determined using a Cecil 9500 Super Aquarius.
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5.2.1 The effects of the addition of surfactants on the Konig reaction
The individual absorbance maximum was determined for each condensing reagent with 
and without the addition of one of the six surfactants under investigation. A standard 
cotinine solution (1 mL, 10 pg/mL) was taken and allowed to react with sodium acetate 
buffer (200 pL, 4 M, pH 4.7), surfactant (200 pL, 0.5 M or 2x105 ppm) or distilled 
water (control sample, 200 pL), potassium cyanide or potassium thiocyanate (200 pL, 
10 % w/v) and chloramine-T (200 pL, 10 % w/v). The reaction mixture was mixed well 
before the addition of a condensing reagent (1 mL, 1% w/v, DETB and DMDD 50:50 
acetone: water v/v, DBTB and MPED, 100 % acetone). The reaction mixture was again 
mixed well and allowed to stand for 20 minutes, before being transferred to a cuvette. 
Measurements were then taken between 450 nm and 550 nm to determine the maximum 
absorbance.
Once the maximum absorbance had been determined for each sample, the procedure 
was repeated in duplicate again, except measurements were taken at the appropriate 
maximum absorbance (table 5.1).
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POTASSIUM THIOCYANATE POTASSIUM CYANIDE
Condensing Surfactant Maximum Surfactant Maximum
reagent (concentration) absorbance (concentration) absorbance
DETB Control 530 Control 525
DETB NCPC (0.5 M) Cloudy NCPC (0.5 M) 526
DETB TTBB (0.5 M) 538 TTBB (0.5 M) 528
DETB Triton X-100 (0.5 M) 539 Triton X-100 (0.5 M) 539
DETB SDS (0.5 M) 535 SDS (0.5 M) Cloudy (pink)
DETB DBS (2x10* ppm) 534 DBS (2x103 ppm) 534
DETB Triton X-200 
(2x105 ppm)
Cloudy Triton X-200 
(2x105 ppm)
530
DBTB Control 532 Control 531
DBTB NCPC (0.5 M) 538 NCPC (0.5 M) 537
DBTB TTBB (0.5 M) 538 TTBB (0.5 M) 535
DBTB Triton X-100 (0.5 M) 532 Triton X-100 (0.5 M) 540
DBTB SDS (0.5 M) 535 SDS (0.5 M) 535
DBTB DBS (2x10" ppm) Cloudy DBS (2x103 ppm) Cloudy
DBTB Triton X-200 
(2x105 ppm)
Cloudy Triton X-200 
(2x105 ppm)
Cloudy
DMDD Control 496 Control 496
DMDD NCPC (0.5 M) Cloudy NCPC (0.5 M) 505
DMDD TTBB (0.5 M) 495 TTBB (0.5 M) 502
DMDD Triton X-100 (0.5 M) 497 Triton X-100 (0.5 M) 500
DMDD SDS (0.5 M) 496 SDS (0.5 M) 497
DMDD DBS (2x103 ppm) 496 DBS (2x103 ppm) 496
DMDD Triton X-200 
(2x105 ppm)
493 Triton X-200 
(2xl05 ppm)
498
MPED Control 498 Control 499
MPED NCPC (0.5 M) 502 NCPC (0.5 M) 503
MPED TTBB (0.5 M) 502 TTBB (0.5 M) 500
MPED Triton X-100 (0.5 M) 500 Triton X-100 (0.5 M) 500
MPED SDS (0.5 M) 498 SDS (0.5 M) 500
MPED DBS (2x103 ppm) Cloudy DBS (2x103 ppm) Cloudy (yellow)
MPED Triton X-200 
(2x105 ppm)
Cloudy Triton X-200 
(2x105 ppm)
Cloudy (yellow)
Table 5.1: Maximum absorbance values for the different condensing reagents with and 
without the addition of surfactants.
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5.3 Results
5.3.1 The effect of surfactants on the Konig reaction when using potassium 
thiocyanate
The results for the various condensing reagents using potassium thiocyanate are shown 
in figures 5.5- 5.8. They suggest the addition of a surfactant to the reaction mixture can 
either cause the absorbance value to increase, decrease or stay the same as the control 
absorbance.
The addition of the cationic surfactants, NCPC and TTAB, overall reduced the 
absorbance values obtained, except, when NCPC was used with the condensing reagent 
MPED, where the absorbance value increased by 143 percent. The addition of the non­
ionic surfactant, Triton X-100, had no real effect on the absorbance value when DETB 
and DMDD were used. However, the absorbance decreased when DBTB and MPED 
were used by 71 percent and 86 percent respectively.
The anionic surfactant, SDS caused a significant increase when either DMDD or MPED 
were used, with an increase of 135 percent and 278 percent respectively. Other anionic 
surfactants, DBS and Triton X-200, were studied but they did not have the same effect 
on absorbance value as SDS. The addition of Triton X-200 to the reaction mixture 
caused the solution to become cloudy for all samples, except when DMDD was used. 
The addition of DBS caused an increase in the observed absorbance when DETB and 
DMDD were used by 22 percent and 142 percent respectively, although the solution 
turned cloudy when DBTB and MPED were used. The reason why the solution turned 
cloudy could be due to the increased amount of acetone present in the DBTB and 
MPED solutions. This may be because DBS is only soluble when a small amount of 
acetone is present, and as DBTB and DMDD are in 100 percent acetone, DBS is no 
longer soluble in the reaction mixture causing the solution to turn cloudy.
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Figure 5.8 The effects of different surfactants on the Konig reaction using MPED and 
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5.3.2 The effect of surfactants on the Konig reaction when using potassium cyanide
The results for the various condensing reagents using potassium cyanide are shown in 
figures 5.9- 5.12. The addition of the cationic surfactant TTAB caused the absorbance 
to decrease, except, when the condensing reagent DMDD was used, where a slight 
increase of 12 percent was observed. However, the addition of NCPC caused an 
increase of 20 percent and 23 percent in the absorbances observed when DETB and 
DBTB were used respectively, and a slight increase of 11 percent when DMDD was 
used.
The addition of Triton X-100 caused the absorbance value to increase when DETB and 
DBTB were used by 37 percent and 19 percent respectively, although no significant 
change was observed using DMDD or MPED.
The addition of Triton X-200 caused all samples to form a precipitate, except when 
DMDD was used. The addition of DBS caused the absorbance to increase when DETB 
and DMDD were used but when the condensing reagents DBTB and MPED were used 
the solution turned cloudy. The addition of SDS caused the absorbance to increase by 
45 percent when DBTB was used, although when used with the condensing reagent 
DETB the solution turned cloudy.
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Figure 5.10 The effects of different surfactants on the Konig reaction using DBTB and 
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5.4 Discussion
Overall, the results suggest that certain surfactants can affect the absorbance value of 
cotinine, when derivatized with various condensing reagents. However, there appears to 
be no set pattern confirming that a particular type of surfactant, for example anionic or 
cationic, or condensing reagent will overall enhance the observed absorbance. Unlike 
the other studies described earlier in the chapter (Esteve-Romero et al 1995, Egekeze et al 1997 
and Capella-Peiro et al 2001) the derivative of cotinine formed in this current study will not 
carry a charge at pH 4.7 and therefore would not be expected to be attracted to either 
anionic or cationic micelles. Therefore, the observed increase in absorbance with the 
addition of various surfactants may be due to hydrophobic interactions. This 
observation was also reported by Esteve-Romero et al (1995) as an explanation for the 
increased absorbance when NCPC was added to a nicotinic acid and aniline solution.
The observed absorbance for potassium thiocyanate did increase especially when the 
anionic surfactant, SDS and the condensing reagent MPED (sample 1) were used. 
However, when comparing the absorbance of the control sample for potassium cyanide 
and MPED (sample 2), the results clearly showed that the absorbance for sample 1 was 
77 percent less than sample 2. Therefore, the results in this study suggest that when 
using potassium thiocyanate and a surfactant such as SDS, the improvement in the 
sensitivity is unequal to the sensitivity when using potassium cyanide alone, although 
overall the increase in absorbance was greater for potassium thiocyanate than potassium 
cyanide. The maximum increase in the absorbance when using potassium cyanide was 
45 percent using SDS and DBTB compared to 278 percent for potassium thiocyanate 
with SDS and MPED. However, the results obtained when using potassium thiocyanate 
do suggest that it may be possible to distinguish urine samples taken from non-smokers 
and heavy smokers, although it can be concluded that it is unlikely that an alternative 
device will be manufactured as it would be extremely difficult to distinguish non- 
smokers from light or social smokers.
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In this current study the experiments performed focused on determining if a particular 
type of surfactant; anionic, cationic or non-ionic surfactant could overall increase the 
observed absorbance, regardless of which condensing reagent was used. Further work 
could be carried out to determine the effects of changing the pH of the reaction, as it 
would be expected that if the derivatized metabolite was protonated it would be 
attracted to anionic micelles, such as SDS, whereas a deprotonated derivatized 
metabolite would be attracted to cationic micelles, such as NCPC. The concentration of 
surfactant could be altered to determine if an increase in the concentration increased the 
sensitivity of the reaction. The mode of delivery of the surfactant could also be 
changed. This could involve changing the order in which the surfactant was add to the 
reaction mixture, as it may be more appropriate to add the surfactant in a different step 
and also investigating the possibility of adding the surfactant to one or more of the 
reagents, thus reducing the number of steps involved.
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Chapter 6
Conclusion
The work described in this study relates to a body of fundamental work regarding the 
use of the Konig reaction for the colorimetric determination of nicotine and its 
metabolites. The first part of the study involved the synthesis of two novel non-polar 
condensing reagents, DBTB and MPED, and a detailed analysis of the Konig reaction in 
relation to these and other condensing reagents. Molar absorptivities and partition 
coefficients were determined for nicotine and 10 of its metabolites using four 
condensing reagents (DETB, DBTB, DMDD and MPED). The results suggested that, 
contrary to the traditional assumptions, each metabolite had its own unique molar 
absorptivity which varied depending on the condensing reagent used. This finding has 
profound implications for the interpretation of the reaction when used quantitatively as 
a test for “Total Nicotine Metabolites” since it is increasingly recognised that nicotine 
metabolism may differ between individuals, ethnic groups and during different 
physiological states. In addition its possible utility as a colorimetric derivatisation 
procedure for the determination of nicotine metabolite concentrations by HPLC may 
also be compromised if cotinine alone is used for standardisation purposes.
Partition coefficients were determined for the Konig derivatives of nicotine and its 
metabolites when extracted into ethyl acetate. It was originally hypothesised that the 
synthesis of the more non-polar derivatives would improve that partitioning between the 
coloured derivatives and ethyl acetate, and thus enhance the analytical sensitivity of the 
reaction. The results showed that there was an increase in the relative partition 
coefficients when the more non-polar condensing reagents, especially MPED, was used. 
Overall it is possible that MPED has the potential to increase the sensitivity of the 
Konig reaction and may also prove to be a more suitable condensing reagent when 
carrying out analytical procedures such as HPLC or for the design of a near patient test.
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The novel derivative DBTB was investigated in relation to a specific radioimmunoassay 
(RIA) for cotinine and the ability of the test to discriminate between smokers and non- 
smokers in clinical samples. When the Konig reaction was used qualitatively DBTB 
overall was the most efficient reagent. Quantitative results suggested that the optimum 
clinical sensitivity and specificity was achieved using DETB. However, the clinical 
sensitivity and specificity for DBTB was only 2 to 3 percent less than that observed 
using DETB. Therefore, the difference in sensitivity and specificity may be due to one 
or two urine samples with a cotinine concentration around the cut off point being 
misclassified. Nonetheless, an excellent correlation was found between the RIA and the 
use of the Konig reaction when using both condensing reagents. However, the use of 
the simple colourimetric procedure has several distinct advantages over the 
conventional RIA. It is considerably cheaper, quick, and gives almost perfect 
discrimination between smokers and non-smokers using no more sophisticated 
equipment than the human eye.
There has been considerable debate as to the precise nature of the derivatives formed 
during the Konig reaction. Two structures have been proposed, by O’Doherty et al 
(1990) and Rustemeier et al (1993). However, O’Doherty et al gave no evidence as to 
why they had suggested their structure, whereas Rustemeier et al isolated the nicotine 
derivative and subjected the compound to various analytical procedures before they 
decided on a final structure. In this current study the nicotine derivative formed when 
using DETB was isolated and analysis using mass spectrometry, IR and NMR was 
carried out. The results strongly suggested that the only evidence was for the structure 
proposed by Rustemeier et al and thus we can now report with some confidence the 
precise nature of the products formed in this reaction.
The work concludes with a consideration of the possible use of surfactants to enhance 
the absorbance obtained in the reaction and enable the use of potassium thiocyanate 
rather than potassium cyanide. Several combinations of anionic, cationic and neutral 
surfactants were investigated with the largest increase in absorbance being observed 
when using potassium thiocyanate with the anionic surfactant SDS. Despite this finding
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the absorbance remained disappointingly less than when potassium cyanide was used on 
its own.
Overall, this current study has pressed the Konig reaction to its limits, leaving very few 
avenues left to investigate. However, since the relative partition coefficients were 
significantly higher when MPED was used, MPED may yet prove to be a more 
appropriate condensing reagent by increasing the sensitivity of the reaction, perhaps 
enabling nicotine and its metabolites to be detected in saliva where the levels are an 
order of magnitude less than in urine. In addition there may yet be some merit in 
designing another barbiturate derivative incorporating some of the features of the 
MPED molecule.
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Abstract: A simple, quick and inexpensive test for smoking status would be 
useful in a variety of settings. The non-polar barbituric acid derivative 1,3-dibutyl- 
2-thiobarbituric acid (DBTB) is described as a novel derivatisation reagent for 
nicotine and its metabolites in the Konig reaction to assess smoking status. The rel­
ative performance of qualitative methods for assessing smoking status using 
DBTB and the previously employed derivatisation reagent l,3-diethyl-2-thiobar- 
bituric acid (DETB), as well as quantitatively-based methods for determining 
‘total nicotine metabolites’ (TNMs) using these two reagents, were evaluated 
against a cotinine-based radioimmunoassay (RIA) as the ‘gold standard’. Clinical 
sensitivity and specificity for all the approaches studied were in excess of 94%. 
Simple qualitative assessment by eye was superior to quantitatively-based 
measures of smoking status. Correlation between estimation of nicotine meta­
bolites using DBTB, DETB and RIA were good. The most efficient and conve­
nient method to distinguish between smokers and non-smokers was the simple 
qualitative method using the more lipophilic reagent DBTB.
K ey words: Cotinine. Konig reaction. Smoking. Total nicotine metabolites.
Introduction
Smoking is the major preventable cause of mortality 
and morbidity in the western world. Recent evidence 
suggests that about half of all regular smokers will die 
from their smoking habit.1 Whilst smoking preva­
lence is on the decline within the industrialised 
nations, it is increasing in most other parts of the 
world. It has been suggested2 that the most effective 
strategy for reducing the incidence of cardiovascular 
disease, stroke and cancer is to cease smoking.
The efficiency with which smokers smoke their 
cigarettes varies between individuals, and smokers 
often deny their addiction. Smoking cessation initia­
tives, the monitoring of smoking during pregnancy,3 
and epidemiological studies of smoking-related ill­
ness would be facilitated if simple, reliable methods 
were available to identifying smokers and assess their 
daily intake of tobacco-related compounds.
For many years, questionnaires have provided 
information on individual smoking habits; however,
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E-mail: r.f.smith@shu.ac.uk
often they have been found to be incorrect when com­
pared with measurements taken in a laboratory. The 
most widely used marker of tobacco usage has been 
the measurement of cotinine, the primary nicotine 
metabolite. This biomarker has been used largely 
because of its long serum half-life (about 17 hours), 
compared with a half-life of about two hours for nico­
tine.4 Methods for cotinine measurement include gas 
chromatography-mass spectrometry (GC-MS),5,6 
high-performance liquid chromatography (HPLC)7"9 
and immunoassay;1011 these have been applied to a 
wide variety of biological samples including serum, 
saliva, urine and hair.
GC-MS is the most sensitive and specific method 
for the measurement of individual nicotine metabo­
lites, but it is labour-intensive and requires very 
expensive equipment. HPLC lacks sensitivity and 
generally picks out only a few of the individual 
metabolites. Immunoassays can be extremely sensi­
tive but measure only cotinine with variable cross­
reactivity to other metabolites, especially the 3'- and 
5'-hydroxycotinine metabolites, depending on the 
antibody employed.
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Alternative urine-based methods to identify smok­
ers and assess their relative nicotine intakes involve 
the use of modifications (or variants) of the simple 
and inexpensive colorimetric Konig reaction, in 
which orange or pink/red chromophores are formed 
from nicotine and its metabolites, using barbituric 
acid or l,3-diethyl-2-thiobarbituric acid (DETB) as 
condensing reagents, respectively.12 The colours that 
form may be read and compared with the colour pro­
duced by a known concentration of cotinine; alterna­
tively, the colour produced may be extracted into 
ethyl acetate and assessed by eye in order to provide 
an immediate qualitative assessment of the smoking 
status of the individual. Using this method, Smith 
et a l.'3 have reported a sensitivity of 95% and speci­
ficity of 100%, compared with radioimmunoassay 
(RIA), for a qualitative asessment of smoking status.
The modified Konig reaction also has been used to 
develop a simple ‘near patient’ test, using DETB as a 
condensing reagent,1415 for HPLCl6and in flow-injec- 
tion17 analysis. In the original qualitative method of 
Peach et a l.,'2 and subsequent HPLC procedures, the 
DETB-derived chromophores were extracted into 
ethyl acetate.
However, unlike the situation with cotinine, it was 
noted that some of the pink chromophores formed in 
smokers’ urine samples were incompletely extracted 
into ethyl acetate. Therefore, it was argued that these 
probably were derived from much more polar 
metabolites of nicotine, and that the extractability of 
the reaction products might be considerably enhanced 
—  and the sensitivity improved —  if a more lipophilic 
barbituric acid derivative was employed. Hence the 
rationale for the synthesis of l,3-dibutyl-2-thiobarbi- 
turic acid (DBTB).
Materials and methods
Potassium cyanide, chloramine-T and sodium acetate 
were purchased from Merck eurolab Ltd. (Lutterworth, 
UK). Acetic acid was purchased from Fisher Scientific 
Ltd. (Loughborough, UK) l,3-dibutyl-2-thiobarbituric 
acid was synthesised using 1,3-dibutyl-2-thiourea and 
diethylmalonate, which were purchased from Aldrich 
(Gillingham, UK). Methanol, ethyl acetate and acetone 
were all of HPLC grade. The absorbencies of the urine 
samples derivatised with either DETB or DBTB were 
measured using a Cecil 9500 Super Aquarius. The iden­
tity of the synthesised DBTB was confirmed by nuclear 
magnetic resonance (NMR), using a Bruker AC 250.
Subjects
During a previous study, urine samples were col­
lected from 251 patients attending the diabetic clinic 
at Ealing Hospital.12 According to the gold-standard
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cotinine RIA method, this population was judged to 
comprise 130 non-smokers and 120 smokers, with 
one result regarded as borderline. The current study 
utilised aliquots of the 224 urine samples (106 smok­
ers, 118 non-smokers) remaining from the Ealing 
Hospital investigation, whose volumes were suffi­
cient for the colorimetric analyses described below.
Samples were subjected to both qualitative assess­
ment of smoking status and quantitative analysis by 
comparison with a standard cotinine preparation. 
Quantitative measurements were made before and 
after extraction with ethyl acetate, although the mea­
surements taken after extraction with ethyl acetate 
were carried out on only 95 of the samples from RIA- 
confirmed smokers and on 115 samples from RIA- 
confirmed non-smokers. All samples were collected 
in accordance with the ethical code used at Ealing 
Hospital. All samples were deep-frozen until analysis 
and all analyses were carried out ‘blind’, without 
reference to the results of the RIA.
Preparation o f  1,3-dibutyl-2-thiobarbituric acid
DBTB was prepared according to the method of Hahn 
et al.'* Briefly, 6.5 g sodium (washed with petroleum 
spirits and dried) was placed in a round-bottomed 
flask containing 75 mL methanol. 10 g N,N-dibutyl- 
thiourea (0.076 mol) and 17.2 g diethylmalonate 
(0.1 mol) were added to the flask, and the resulting 
reaction mixture was allowed to reflux for 36 h.
After this period, 50 mL distilled water was added 
and partly evaporated under pressure to remove any 
remaining methanol. The small amount of white pre­
cipitate (unreacted dibutylthiourea) formed during 
this evaporation was removed by filtration. The solu­
tion was diluted further with 100 mL distilled water, 
chilled on ice and then acidified with concentrated 
hydrochloric acid to between pH 1 and 2.
The resulting precipitate was collected and dried 
under reduced pressure to produce a light yellow  
powder of DBTB. The melting point range was 
between 56"C and 60°C. An NMR scan was carried 
out to confirm the identity of the compound— 'H 
NMR (250 MHz; CDC13) 8 ppm 0.94 (6H, t, J  7.5,CH, 
x2); 1.35 (4H, m, CH,CH,CH3); 1.6 (4H, m, 
CH,CH,CH3) 3.7 (2H, s, 0=CCH2C=0; 4.3 (4H, t, J 
7.5-NCH2CH2-).
Cotinine radioimmunoassay
For the purpose of this study, RIA was used as the 
gold-standard test. This is a well-documented method 
that can reliably distinguish between two categories; 
for example, an individual that is exposed to high lev­
els of nicotine (i.e. a smoker) and an individual who is 
exposed to low levels of nicotine (i.e. a non-smoker).
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Urinary cotinine concentrations were determined by 
RIA,11 as described previously.12 Aliquots (10 pL) of 
the samples or cotinine calibrators (0.14-4.26 pmol/L) 
were incubated overnight with cotinine antibody and 
radioactive iodine (l23I)-labelled cotinine. Bound and 
free fractions were separated using a polyethylene- 
glycol-assisted second antibody technique. The radio­
activity in the bound fraction was counted, and cotinine 
concentrations were estimated using a four-parameter 
logistic curve-fitting programme. Within- and between- 
batch imprecisions were 5.1 % and 7%, respectively.
Konig reaction
The total nicotine metabolite concentration was 
determined both qualitatively and quantitatively. 
Briefly, this involved adding 1 mL of individual 
nicotine metabolite, urine, or standard cotinine solu­
tion to 400 pL sodium acetate buffer (pH 4.7). This 
was followed by addition of 200 pL potassium 
cyanide (10% w/v) and 200 pL chloramine-T (10% 
w/v). The solution was mixed well before the addi­
tion of condensing reagent (1 mL; DETB [1% w/v, 
watenacetone 50:50] or DBTB [ 1 % w/v in acetone]). 
The reaction mixture was again mixed well and 
allowed to stand for 20 min. Absorbance measure­
ments were made both before and after extraction 
with ethyl acetate (1 mL).
Qualitative assessment was by simple observation 
of a pink colour in the ethyl acetate layer. Absorbence 
of unextracted and ethyl-acetate-extracted samples 
was measured at 525 nm and 533 nm, respectively. A 
stock solution of 28 pmol/L cotinine (5 pg/mL) was 
used to determine the equivalent nicotine metabolite 
concentration. In addition, a sample blank was used, 
which comprised a mixture of urine samples from 
both self-reported smokers and non-smokers, and was 
assayed following the basic method, except that the 
chloramine-T was omitted.
Results
Urinary concentrations determined by cotinine RIA 
ranged from 0.06 pmol/L to 0.97 pmol/L (median:
0.1 pmol/L) for non-smokers, and from 1.48 pmol/L 
to 76.5 pmol/L (median: 19.3 pmol/L) for smokers.
Urinary concentrations determined using DETB 
ranged from <0.1 pmol/L to 12.9 pmol/L (median:
1.25 pmol/L) for non-smokers, and 4.32 to 
282 pmol/L (median: 45 pmol/L) for smokers.
Urinary concentrations determined using DBTB 
without extraction ranged from <0.1 pmol/L to 
9.8 pmol/L (median: 4.29 pmol/L) for non-smokers, 
and 5.17 pmol/L to 324 pmol/L (median: 30.3 pmol/L) 
for smokers.
When measurements were made post-extraction 
(DBTB only), results ranged from <0.1 pmol/L to 
12.6 pmol/L (median: 0.91 pmol/L) for non-smokers, 
and 2.56 pmol/L to 212 pmol/L (median: 23.8 pmol/L) 
for smokers (Table 1).
The optimum cut-off point between smokers and 
non-smokers using DBTB was determined by 
receiver operator characteristic (ROC) curve ana- 
lysis13 from a consideration of sensitivity and speci­
ficity when compared with the gold-standard RIA 
determination. Sensitivity was calculated as the pro­
portion of true positive (TP) test results obtained in 
subjects who smoked (i.e. TP/TP + FN [false nega­
tives]), whereas specificity was calculated as the pro­
portion of true negative (TN) results obtained in sub­
jects who did not smoke (i.e. TN/TN + FP [false 
positives]). Overall test efficiency was calculated as 
TP + TN/TP + FP + TN + FN. The cut-off point for 
DBTB unextracted was determined as 8.5 pmol/L, 
compared with 4 pmol/L for samples extracted in 
ethyl acetate.
Using DETB, qualitative assessment of smoking 
status gave a sensitivity of 94% and specificity of 
100%. Using DBTB, sensitivity and specificity were 
100% and 99%. respectively. There was an overall 
improvement in efficiency from 97% with DETB to 
99.5% with DBTB. When the samples were analysed 
quantitatively, results for DETB-unextracted samples 
gave a sensitivity and specificity of 98%. DBTB- 
unextracted samples produced a sensitivity and speci­
ficity of 95% compared with results obtained from 
samples using DBTB extracted in ethyl acetate, which 
gave a sensitivity and specificity of 96% (Table 2).
Table 1. Urinary cotinine and TNM values in smokers and non-smokers (pmol/L)
Non-smokers Smokers
Median Range Median Range
RIA 0.1 0.06-0.97 19.3 1.48-76.5
DETB 1.25 < 0.1-12.9 45 4.3-282
DBTB 4.29 < 0.1-9.8 30.3 5.2-324
DBTB (post-extraction) 0.91 < 0.1-12.6 23.8 2.6-212
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Table 2. Sensitivity and specificity o f barbiturate derivatives, 
compared with the RIA gold standard
Sensitivity Specificity
Qualitative
DETB 94% 100%
DBTB 100% 99%
Quantitative
DETB 98% 98%
DBTB (post-extraction) 95% 95%
DBTB 96% 96%
Amongst the smokers, correlation between urinary 
cotinine measurement (RIA) and the colorimetric 
procedures was determined using Spearman’s Rank 
analysis. DBTB extracted (n = 95): rs = 0.84, P  <0.01 
(Figure 1); DBTB unextracted (n = 106): rs = 0.790, 
P  <0.01. Correlation between DETB and DBTB 
unextracted (n = 106) gave rs = 0.871, P  <0.01.
Discussion
There is a need for a quick, simple, inexpensive test to 
assess smoking status in a variety of settings. Several 
workers have attempted to employ the Konig reaction 
for this purpose. The approach employed here —  that 
is, attempting to improve assay sensitivity by use of a 
more non-polar derivatisation reagent, allied to 
extraction of the coloured product —  yielded good
results. Qualitative assessment of smoking status was 
clearly superior to quantitative determination. The 
increase in partitioning between the aqueous and 
ethyl acetate phases, obtained using DBTB, improves 
distinction between non-smoker and smoker, from an 
overall efficiency of 97% with DETB to 99.5% with 
DBTB. However, this distinction is notoriously diffi­
cult to make because no individuals truly can be said 
to not be exposed to tobacco smoke; and in any study 
of this type, the numbers of subjects appearing at the 
cut-off point is usually small.
Use of this compound offers clear advantages, 
both for HPLC analysis and for use in small near­
patient devices for monitoring exposure to environ­
mental tobacco smoke.19 Correlation between RIA 
and colorimetric methods is good, but the results 
clearly are skewed by one or two subjects who had 
levels of total nicotine metabolites proportionately 
higher compared with cotinine. The implication is 
that these individuals may metabolise nicotine dif­
ferently to the majority.
This is in accordance with the recent finding of null 
alleles for the cytochrome P450 enzyme CYP2A6, 
which is important in the metabolism of nicotine.20 
Individuals who cannot metabolise nicotine, or who 
metabolise nicotine poorly via the P450 pathway, may 
have greater amounts of other nicotine metabolites, 
which are measured in the Konig reaction but not by 
RIA.
Recent work suggests that nicotine is metabolised 
differently in the pregnant and non-pregnant
Spearman's rank n = 95 
rs = 0.847, P<  0.01
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Fig. 1. Correlation between DBTB (extracted) and cotinine RIA.
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individual,21 and that there are inter-racial differences in 
nicotine metabolism.22 The novel derivative described 
in this paper provides an improved, simple, inexpensive 
and near-perfect test for the determination of smoking 
status.
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